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Abstract 
Exploring the mechanism of SHP2 and EGFR/HER2 
cooperation in breast cancer cell signaling 
Zachary Raymond Hartman 
The Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) has been established as a 
critical mediator of cancer-related cell signaling downstream of receptor tyrosine kinases like EGFR 
and HER2. As such, targeting of SHP2 is being recognized as a potentially viable therapeutic option 
in HER2-positive and triple-negative breast cancers. In this report, I employed molecular and 
cellular biology techniques to further elucidate the role of SHP2 downstream of receptor tyrosine 
kinases in breast cancer cell lines. In this way, I was able to contribute knowledge to how SHP2 
controls triple-negative cell motility. In addition, the mechanism of SHP2 control of HER2 signaling 
was investigated in order to better understand how SHP2 positively mediates signaling. The 
EGFR/HER2 heterodimerization axis was also explored, uncovering a mechanism by which HER2 is 
able to protect EGFR from degradation through suppression of phosphorylation at specific sites. 
Finally, molecular modeling was used to determine how SHP2 is able to selectively interact with 
endogenous substrates. These studies contribute both to the rationale for targeting SHP2 and the 
mechanism by which SHP2 promotes breast cancer signaling in cooperation with EGFR and HER2. 
The knowledge added by these studies will hopefully contribute in the future toward the 
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1. Introduction 
1.1) Breast cancer public health significance 
Breast cancer is one of the most significant public health concerns for women in the world.  In 
US women, it is the most common form of malignant neoplasm, and, after lung cancer, it is 
responsible for the most cancer-related mortality. The American Cancer Society estimates that 
the number of new breast cancer diagnoses will reach 232,340 in the year 2013, and a total of 
39,620 deaths will result from breast cancer (1).  Prevalence generally increases with age; 
78% of all new diagnoses in 2013 occurred in women above the age of 50 (1). Other significant 
risk factors for developing breast cancer include high breast density, family history of breast 
cancer, alcohol consumption, early menarche, and obesity, among others (1). 
Breast cancer treatment incurs nearly $4.2 billion per year in the US in direct costs (2). 
The indirect costs—time lost from work due to disability or mortality and social impact, etc. – 
are more difficult to estimate, but one study has placed this burden in terms of “short-term” 
(i.e., 12 month) disability and sick leave costs at approximately $3690 per patient with 
primary breast cancer and $6166 per patient with metastatic disease (3).  From these data, it is 
clear that breast cancer represents a profound societal burden. 
1.2) Breast cancer pathogenesis 
Breast cancer, like other forms of cancer, is thought to result from genetic changes in normal 
cells that enhance proliferation and confer escape from physiologic programmed cell death (4). 
The majority (~95%) of breast cancer cases are sporadic in nature, resulting from genetic 
aberrations that accumulate over time due to environmental factors such as exposure to 
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carcinogens. The remaining 5% of breast cancers are hereditary in nature, generally resulting 
from inactivating mutations in the BRCA-1 and BRCA-2 genes that encode E3 ubiquitin ligases 
used in DNA repair (4). Dysfunction of the normal DNA damage response can promote 
genomic instability, increasing the likelihood of mutations that activate proto-oncogenes or 
that inactivate tumor suppressors (4). Accumulation of these mutations can confer the 
hallmarks of cancer: sustained proliferation, evasion of cell cycle control, promotion of 
metastasis, replicative immortality, promotion of angiogenesis, and resistance to apoptosis (5).  
1.3) Classification of breast cancer 
The discovery that ovarectomy, removal of the ovaries to terminate estrogen production, was 
an effective treatment for some, but not all cases of breast cancer indicated that the disease 
was heterogeneous (6). Today, clinicians rely on several techniques to determine the 
phenotype of breast cancer. Immunohistochemistry is used to assess the expression of the 
hormone receptors (estrogen receptor and progesterone receptor, ER and PR) and HER2 
(human epidermal growth factor receptor 2, a proto-oncogenic receptor tyrosine kinase). In 
cases where HER2 expression is equivocal, fluorescence in situ hybridization is used to directly 
determine the copy number of the gene. These data allow clinicians to stratify cases of breast 
cancer into three major types: hormone receptor-positive, HER2-positive, and triple-negative 
(7).   
Recent advances in breast cancer molecular biology has led to the classification of 
breast cancer into five distinct subtypes based on gene expression profiling rather than 
immunohistochemistry and copy number. These include luminal A and luminal B (with a gene 
expression signature matching the hormone receptor-positive luminal cells of the breast), 
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HER2-positive, basal-like (with a gene expression signature matching features of the 
myoepithelial cells of the basal lamina, usually lacking expression of either hormone receptors 
or HER2), and normal-like (with a gene expression signature clustered tightly with the normal 
basal epithelium) (8).  
The hormone receptor-positive disease is the most common form of breast cancer, 
representing approximately 60% of all cases of breast cancer. HER2-positive disease accounts 
for 15-20% of all cases (9), while the triple-negative disease accounts for another 15-20% of 
all cases.  Up to 85% of triple-negative cancers express basal myoepithelial markers like 
cytokeratins 5 and 6 (10).   
1.3.1) HER2-positive breast cancer 
HER2 is the most commonly-dysregulated proto-oncogenic tyrosine kinase that drives breast 
cancer. When it was first characterized, the hormone-dependent forms of breast cancer had 
been effectively treated for nearly two decades (11). HER2 was discovered following 
transformation of normal mouse fibroblasts using DNA harvested from a rat neuroblastoma 
(12). This oncogenic DNA was found to encode a 185 kDa protein (13), and the responsible 
gene was isolated and termed Neu (14). The human homologue of Neu was found a year later, 
and its extensive sequence homology to the epidermal growth factor receptor (EGFR) led 
scientists to name the protein “human epidermal growth factor receptor 2,” HER2 (15). 
Throughout the late 1980s, HER2 was characterized as an important driving force in breast 
cancer, mainly through its gene amplification on Chromosome 17 (16).  
The oncogenicity of HER2 results from dysregulation of its ligand binding domain. 
Normally, EGFR family members require the binding of a ligand to promote dimerization and 
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signal transduction. However, the ligand binding domain of HER2 is constitutively blocked by 
interactions with other nearby domains. This results in an altered conformation of the 
dimerization arm that allows it to associate with other activated EGFR family members (17). 
Overexpression of HER2 promotes the ligand-independent formation of homo- or 
heterodimers. In this way, HER2 can act as a strong potentiator of mitogenic and survival 
signaling, leading to cancer growth and poor prognosis if left untreated (18).  
While it can portend poor outcomes for patients, HER2 overexpression presents two 
unique opportunities for therapy. First, since cancer cells rely on upregulated HER2 for growth 
and survival, inhibition of its activity may selectively harm tumors while largely sparing the 
normal cells in the body. Second, since HER2 possesses a unique extracellular domain, a 
targeted agent may not need to enter the cell to inhibit its function. This was demonstrated for 
the first time in the 1986 when a monoclonal antibody developed against the extracellular 
region of HER2 was found to inhibit growth of HER2-transformed cells (19). This observation 
led to the development of the humanized antibody trastuzumab, which became the first 
therapy designed to target a single molecule in breast cancer (20). The efficacy of trastuzumab 
will be discussed further below. 
1.4) Treatment of breast cancer 
When breast cancer is diagnosed, therapy will be influenced by factors that include the stage of 
the disease (i.e., metastatic versus early-stage disease), tumor grade, and subtype. The 
strategies at clinicians’ disposal include gross techniques such as surgery and radiotherapy as 
well as systemic chemotherapies. 
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1.4.1) Surgery and radiotherapy 
Thanks to improvements in early breast cancer detection, most breast tumors are discovered 
in the pre-metastatic setting (4). Therefore, many patients benefit from resection in the form of 
lumpectomy (removal of tumor sparing the rest of the breast as much as possible) or 
mastectomy (removal of a significant portion or the entirety of the breast). Radiation is often 
prescribed to help eliminate cells that may have escaped surgical removal.  
1.4.2) Systemic, cytotoxic chemotherapy 
As an additional regimen to suppress disease relapse, cytotoxic chemotherapy is often 
prescribed after surgery (the so-called adjuvant setting). These agents target rapidly-dividing 
cells to promote programmed cell death. There are many types of chemotherapeutics available 
to clinicians, including anthracyclines, which intercalate into DNA and RNA to prevent 
replication, alkylating agents, which damage the DNA via alkylation, antimetabolites, which 
interfere with the synthesis of DNA and RNA building blocks, and microtubule inhibitors, 
which disrupt the functions of microtubules to prevent mitosis.  Each of these drug families can 
reduce tumor size and help to prolong survival. Agents are often combined since their 
mechanisms of action and toxicities do not overlap. Nevertheless, cytotoxic chemotherapy is 
highly toxic, producing side effects ranging from the relatively-benign such as hair loss to the 
severe and life-threatening such as cardiotoxicity and sepsis (21).  
1.4.3) Systemic, targeted therapies 
Researchers have long sought a “magic bullet” for cancer to take advantage of the genetic 
aberrations that drive tumor growth and selectively induce apoptosis in cancer cells. To this 
end, many agents have been developed to target specific subtypes of breast cancer. Hormone 
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receptor-positive disease can be treated with selective estrogen receptor modifying drugs such 
as tamoxifen, a competitive inhibitor targeting the receptor, and anastrazole, an aromatase 
inhibitor that disrupts the production of estrogen. HER2-positive disease has been targeted by 
the biologic trastuzumab (Herceptin, Roche). Small molecule inhibitors against the HER2 
kinase domain like lapatinib (Tykerb, GlaxoSmithKline) have also been approved for use in 
HER2-positive disease. 
Targeted therapeutics produce significant benefit for many patients. For example, 
trastuzumab was shown in its pivotal trial to dramatically improve response rate when 
combined with a combination anthracyline-cyclophosphamide regimen (38% response rate 
with no added trastuzumab versus 50% with) and with paclitaxel (15% response rate without 
trastuzumab versus 38% with) (20). As a result, overall survival was improved in metastatic 
breast cancer by 4-9 months due to addition of trastuzumab. Since metastatic breast cancer is 
regarded as incurable, these improved response rates and overall survival benefits have made 
trastuzumab a part of the standard of care for HER2-positive disease. 
While these targeted agents have improved breast cancer therapy, problems persist. 
First, response to therapy is far from a guarantee. Nearly half of patients with clinically-
diagnosed HER2-positive disease fail to respond to trastuzumab therapy (20). This 
observation reflects heterogeneity of breast cancers even within subtypes, and the mechanism 
of this de novo resistance to trastuzumab has yet to be elucidated, though the dichotomy 
between HER2-expressing and HER2-enriched has been forwarded by large-scale analysis of 
breast samples (22). Specifically, only half of the profiled breast tumors that were clinically 
diagnosed as HER2-positive showed enrichment of HER2 mRNA, suggesting they would see 
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limited benefit to trastuzumab therapy. This conclusion has yet to be formally tested in a 
prospective clinical trial, however. Second, acquired resistance is common in targeted 
therapeutics. Biochemical evidence for this phenomenon (e.g., downregulation of the estrogen 
receptor with treatment of tamoxifen) can be observed as early as the first stages of drug 
response (4). With small molecule inhibitors like lapatinib, cancer cells can acquire mutations 
in the target protein that make it resistant to binding by the inhibitor (e.g., mutation of the ATP 
binding site). Acquired trastuzumab resistance can result from upregulation of secretases such 
as ADAM10 that promote ectodomain shedding (23) or from switching to reliance upon other 
receptor tyrosine kinases to promote growth (24). 
Finally, no targeted therapies exist to address triple-negative breast tumors. 
Nonspecific therapies remain the only option. In addition, since triple-negative disease tends 
to be less differentiated, it is often higher grade, as well, raising the likelihood for disease 
progression and metastasis (10). Therefore, researchers are exploring many routes to develop 
triple-negative cancer-specific therapies. Various agents in clinical trials include inhibitors 
targeting other receptor tyrosine kinases (e.g., erlotinib and pertuzumab that target EGFR), 
PI3K, and chaperones like Hsp90. In support of this approach, a significant proportion of 
triple-negative cancers overexpress EGFR (between 50-70%, depending on the technique used 
to assess expression) (10).  
The challenges associated with therapy in breast cancer cases that involve receptor 
tyrosine kinase signaling, HER2-positive and triple-negative disease, point to possibilities in 
targeted therapy downstream of receptors. The remainder of this report focuses on the Src 
homology 2-containing protein tyrosine phosphatase (SHP2), since it has been shown to 
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promote signaling and transformation downstream of oncogenic receptor tyrosine kinases like 
HER2 (25). As such, it is being recognized as a master regulator of pro-tumorigenic signaling 
that is an attractive target for therapy in different forms of cancer, including breast cancer 
(26). Breast cancer, in particular, has been shown to overexpress either SHP2 protein or 
effectors that contribute to its activation (27,28). 
2) The tyrosine phosphatase SHP2 
 
2.1) Protein tyrosine phosphatases: introduction and catalytic mechanism 
 
Phosphorylation of serine, threonine, and tyrosine residues governs many cellular functions. 
Many oncogenes characterized so far promote tyrosine phosphorylation (e.g., Src kinase and 
HER2), making this phenomenon especially important in oncology. 
Cellular levels of tyrosine phosphorylation are governed by the interplay between 
kinases and phosphatases, which add or remove phosphate groups, respectively. Tyrosine 
kinases are pivotal in the transduction of proliferative signals and are common drivers of 
cancer development and progression (29). To this end, therapeutic targeting of tyrosine 
kinases is an intense focus of the pharmaceutical industry, occupying 50-70% of all cancer 
drug development efforts (30). 
Tyrosine phosphatases counter the action of tyrosine kinases. These enzymes include 
two major families: receptor-type (RTPTP) and cytosolic protein tyrosine phosphatases (PTP). 
PTPs comprise more than 100 different members that have a highly-conserved active site 
motif defined by the sequence HCXXGXXRS (Fig. 1) (31,32). When a phosphotyrosine residue 
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or similar substrate enters the active site, the conserved arginine helps to attract and position 
the negatively-charged phosphate moiety (Fig. 1). Histidine coordinates with the catalytic 
cysteine thiol, lowering its pKa and helping to form a thiolate. Nucleophilic attack of the 
phosphate facilitated by an aspartic acid from the WPD loop, acting as a proton donor, results 
in the formation of a thiol phosphate intermediate and a free tyrosine residue that diffuses 
from the active site. The deprotonated aspartate then functions as a general base to catalyze 
hydrolysis of the intermediate, releasing inorganic phosphate and resetting the enzyme (32).  
 
Figure 1. PTP catalytic mechanism. Nucleophilic attack by the catalytic cysteine is facilitated by 
the aspartate of the WPD loop and the arginine of the catalytic motif followed by hydrolysis 
catalyzed by the aspartate to yield inorganic phosphate and a free enzyme (33). 
2.2) SHP2 discovery and initial characterization 
 
Throughout the 1980s and into the early 1990s, mediators of EGFR and other receptor 
tyrosine kinases were discovered and characterized in Drosophila. One such gene, Corkscrew 
(Csw), was identified as a mutation in the receptor tyrosine kinase Torso pathway. Csw was 
shown to promote the activation of this signaling parthway (31). In 1992 and 1993, the 
mammalian ortholog was discovered by five different groups, each giving the protein product a 
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different name (Syp, SH-PTP2, SH-PTP3, PTP1D, and PTP2C) (34-38). Researchers noted the 
sequence similarity between this new tyrosine phosphatase and the Csw gene product, 
suggesting that a mammalian phosphatase could play a positive role in signaling (35). The 
naming convention of the protein was eventually unified as the SH2-containing protein 
tyrosine phosphatase 2 (SHP2); this standardization was formalized in a letter to Cell in 1994. 
(Dr. Benjamin Neel, personal communication) 
2.3) Structural regulation of SHP2 
 
Aside from its active site, SHP2 has several important structural features. It contains two SH2 
domains arranged tandemly that help to regulate SHP2 activity (29). The N-terminal SH2 
domain (N-SH2) sits atop the active site, preventing access by phosphotyrosine substrates 
(39). When the N-SH2 domain engages a phosphotyrosine, conformational changes within the 
SH2 domain weaken the association with the active site, promoting an open conformation that 
is exposed to substrates (Fig. 2). The N-SH2 domain acts as both an activity gatekeeper and a 
trafficking regulator, promoting SHP2 localization to areas of high phosphotyrosine content. 
This dichotomy between the “closed” and “open” configurations of SHP2 is thought to be the 
most important means of regulating activity. The C-terminal SH2 domain does not function as a 
direct inhibitor of the active site in the same way. It is thought to further promote SHP2 
trafficking; however, its full function is not known. 
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Figure 2. Mechanism of SHP2 structural regulation. SHP2 is kept in an inactive, “closed” conformation under 
normal conditions. Activation of receptors in the cell results in upregulation of membrane tyrosine 
phosphorylation that promotes SHP2 translocation. Engagement of the SH2 domains weakens the association of 
the N-terminal SH2 domain with the catalytic domain, rendering SHP2 active near its substrates (40). 
  
SHP2 also contains a C-terminal tail with two phosphorylatable tyrosine residues. When 
phosphorylated, they are able to act as docking sites for SH2-containing proteins such as 
growth factor receptor-bound 2 (Grb2) (41). When these tyrosines are mutated to 
phenylalanine, fibroblast growth factor and platelet-derived growth factor-induced signaling 
are inhibited (41). A proline-rich region is also located in the C-terminus, but its function has 
yet to be elucidated (26).  
2.4) SHP2 in normal cell signaling 
 
2.4.1) SHP2 in mitogenic signaling 
 
SHP2 and its orthologues (i.e., Csw in D. melanogaster) are essential for the development of 
numerous animal models, including C. elegans (42), D. melanogaster (43), X. laevis (44), and M. 
musculus (45). The primary role of SHP2 in these systems appears to be control of Ras-
mediated mitogenic signaling downstream of growth factor receptors. Among the first of these 
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growth factor receptor pathways shown to be SHP2 dependent was that of the platelet-derived 
growth factor receptor (PDGFR) (46). SHP2 control of this signaling pathway is multifactorial 
(Fig. 3). First, SHP2 directly controls phosphorylation levels of the receptor following 
stimulation of cells with PDGF (46). In addition, SHP2 can become phosphorylated in response 
to PDGF (41). Phosphorylation of both tyrosine residues of SHP2’s C-terminal tail is required 
for maximal induction of mitogen-activated protein kinase (MAPK) signaling in response to 
PDGF. Mutation of these residues, however, did not abolish activation of the pathway 
promoted by SHP2, suggesting other mechanisms of regulation. Analysis of the Torso pathway, 
the near-equivalent of PDGFR in D. melanogaster, provides a clue into the other roles of SHP2 
in PDGF signaling. Csw dephosphorylates the phosphotyrosine responsible for recruiting the 
Drosophila homologue to the Ras GTPase activating protein (RasGAP), regulating signaling in a 
manner similar to EGFR in mammalian cells, discussed below (47). 
Other extensively-studied growth factor cascades mediated by SHP2 include the 
fibroblast growth factor (FGF) and epidermal growth factor (EGF) pathways. Signaling is 
initiated by ligand binding to the receptor, promoting receptor dimerization. This induces 
conformational changes in the juxtamembrane domain, positioning the kinase domain of one 
molecule near the C-terminal tail of its partner and inducing phosphorylation of multiple 
tyrosine residues. Phosphorylation allows for the recruitment of SH2 domain-containing 
molecules that act as either enhancers or inhibitors of signaling. For example, Grb2 contains an 
SH2 domain that binds to phosphotyrosines of EGFR, and it acts as a scaffold that recruits the 
Son of Sevenless (SOS), allowing the latter’s pleckstrin homology domain to interact with 
nearby phospholipids, relieving SOS autoinhibition. This promotes the guanine exchange factor 
activity of SOS, converting inactive Ras-GDP into the active Ras-GTP and resulting in 
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subsequent activation of the MAPK pathway (48). At the same time, negative regulatory 
proteins are recruited to phosphotyrosines in order to attenuate the signaling cascade. One 
such negative event is phosphotyrosine 992 recruitment of p120 RasGAP, which promotes the 
intrinsic GTPase activity of Ras and the conversion of Ras-GTP into Ras-GDP. SHP2 is able to 
suppress this negative regulation by directly dephosphorylating phosphotyrosine 992, 
excluding RasGAP binding and therefore promoting Ras activity (49). Similar regulation of 
RasGAP binding to HER2 phosphotyrosine 1023 has been observed (25). 
SHP2 promotes mitogenic signaling through EGFR in other ways, as well. It can directly 
dephosphorylate the inhibitory Sprouty protein (50), and it can downregulate the activity of 
the c-Src kinase (Csk), relieving repression of Src after growth factor stimulation (51).  
 
Figure 3. Growth factor signaling can be regulated by SHP2 through the direct 
dephosphorylation of receptors (e.g., inhibition of RasGAP recruitment) or other mediators 
(e.g., dephosphorylation of Csk to ultimately activate Src) (52). 
 
2.4.2) SHP2 in cell survival 
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In addition to promoting mitogenic signaling, SHP2 is an important player in cell survival (31). 
This aspect of SHP2 biology has been observed in several growth factor and cytokine signaling 
contexts. Expression of dominant negative SHP2 abolishes Akt phosphorylation due to either 
EGF or insulin-like growth factor 1 stimulation, demonstrating its importance in growth factor-
induced pro-survival signaling (45,53). Fibroblasts deficient in Akt signaling due to SHP2 
inactivation are more susceptible to etoposide-induced apoptosis compared with normal cells 
(54). 
Similar to its promotion of mitogenic signaling, SHP2 action on tyrosine 992 of EGFR or 
the analogous tyrosine 1023 of HER2 is important for promoting EGF-induced Akt signaling 
(25,49). Mutation of these residues to phenylalanine enhances Akt activation in response to 
EGF stimulation. The mechanism of this negative regulation by SHP2 substrate sites has not 
been fully elucidated, though some studies show a correlation between Ras activation and 
downstream Akt phosphorylation (55,56). 
SHP2 also functions in cytokine-mediated signaling cascades. Cytokines participate in a 
cascade involving cytokine receptor, which recruits the Janus kinase (JAK) following binding to 
the cytokine in its extracellular domain. In turn, JAK phosphorylates the receptor, promoting 
the recruitment of signal transducers and activators of transcription (STATs). JAK is then able 
to phosphorylate the recruited STAT molecules, stimulating their dimerization. STAT dimers 
translocate to the nucleus and mediate transcription of target genes. Induction of STAT5, in 
particular, is regulated by SHP2 in both cell culture following prolactin stimulation (57) and 
during pregnancy and lactation in mice (58). In addition, interleukin or tumor necrosis factor-
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α-induced production of interleukin-6 is blunted in SHP2 -/- fibroblasts, showing that SHP2 
can also control upstream cytokine signaling (59). 
2.4.3) SHP2 in cell fate 
 
Abrogation of SHP2 activity induces embryonic lethality during mid-gestation, in part due to 
accumulation of undifferentiated cells in the primitive streak, which results in failure to derive 
the mesodermal tissue lineage (60). This observation is strong evidence in favor of a role for 
SHP2 in controlling cell differentiation.  In another study, embryonic stem cells derived from 
SHP2-null mice were shown to be less able to differentiate to hemangioblasts in culture 
(53,59). Conditional deletion of SHP2 in the thymus by driving the expression of Cre 
recombinase through the Lck promoter inhibited the expansion of CD4+ T-cells, consistent 
with a defect in Ras/MAPK-related signaling in these cells (61).  
2.4.4) SHP2 in cell motility 
 
Embryonic lethality in SHP2-null mice is not due only to defective cell differentiation. Defective 
mesodermal patterning is also observed in these embryos (62). This observation suggests 
SHP2 is important in gastrulation, similar to the phenomenon observed with focal adhesion 
kinase or fibronectin knockout animals (62). This suggested that SHP2 played an important 
role in motility and adhesion signaling. Indeed, embryonic fibroblasts with no SHP2 activity 
exhibit aberrant focal adhesion formation and condensation of fibrillar actin at the cell 
periphery. Signaling downstream of FAK and Src following adhesion are inhibited in SHP2-null 
versus wildtype SHP2 fibroblasts (62). These observations were expanded by analyzing 
signaling downstream of integrins (63) and growth factors (64), in both cases showing that 
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SHP2 controlled the tyrosine phosphorylation of proteins involved in adhesion such as FAK, 
paxillin, and p130Cas, and the control of cell migration was only partially dependent on 
enhanced MAPK signaling through SHP2 (64).  
Control of cytoskeletal dynamics by SHP2 was first demonstrated in the RhoA pathway 
by Schoenwelder, et al, suggesting SHP2 signaling results in suppression of RhoA (65). Another 
study in which SHP2 was artificially partitioned to lipid rafts clarified this role of SHP2. During 
adherent conditions, activated SHP2 appeared to suppress RhoA signaling; however, when 
cells were detached, SHP2 promoted RhoA activation (66). 
Aside from control of cytoskeletal dynamics, SHP2 has been implicated in the regulation 
of focal adhesion turnover, an essential process for motility (67). Fibroblasts deficient in SHP2 
produce numerous immature focal complexes, independent of RhoA activation. In addition, the 
dynamics of adhesion proteins was significantly increased in these cells, suggesting SHP2 
somehow participates in the maturation and strengthening of focal adhesions. 
2.5) SHP2 in pathology 
 
Given its importance in normal cell biology, it is not surprising that dysregulation of SHP2 can 
lead to or enhance disease states. In fact, numerous conditions have been linked to SHP2 
hyperactivation or downregulation. This section outlines the phenomena observed during 
SHP2 dysregulation in humans. 
2.5.1) SHP2 in congenital diseases 
 
Germline mutations of PTPN11, the gene that encodes SHP2, are prevalent in Noonan 
syndrome, giving one of the first clues into the significance of SHP2 to human disease. Noonan 
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syndrome, characterized by the development of short stature, craniofacial abnormalities, and 
heart disease, results from missense mutations of SHP2 in more than 50% of cases (68). These 
mutations typically affect the interface between the N-SH2 domain and the catalytic domain of 
the protein, disrupting the interactions and shifting the equilibrium of the protein toward a 
constitutively open conformation. Noonan syndrome is alternatively caused by missense 
mutations that enhance the activity of SOS, promoting dysregulated Ras/MAPK signaling (69). 
This observation and others led researchers to speculate that dysregulated Ras signaling 
promoted by SHP2 is the primary factor leading to Noonan syndrome in patients. 
Paradoxically, LEOPARD (multiple lentigenes, electrocardiographic abnormalities, 
ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, 
sensorineural deafness) syndrome is a generally Noonan-like syndrome but with mutations in 
SHP2 that involve the active site and downregulate its activity (70). The reason for the 
overlapping symptoms of Noonan and LEOPARD syndromes despite opposite effect on 
enzymatic activity has not yet been elucidated (71).  
2.5.2) SHP2 in hematopoietic malignancy 
 
Activating mutations of SHP2 have also been associated with various forms of leukemia, most 
notably in the case of juvenile myelomonocytic leukemia (JMML). In one study, nearly 35% of 
JMML cases demonstrated PTPN11 mutations (72), resulting in enhanced SHP2 activity and 
signaling downstream of EGF. Some of these mutations result in as high as a 12-fold induction 
of SHP2 activation (73). In adult forms of leukemia, SHP2 mutations are rare. Instead, the 
expression of SHP2 is typically elevated in cancer cells compared with normal bone marrow 
(74).  
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A seminal finding in leukemia was the discovery of the Philadelphia chromosome, a 
translocation between chromosomes 9 and 22, resulting in a fusion product between the BCR 
gene and the Abl1 gene that encodes a constitutively-active kinase and leading to chronic 
myelogenous leukemia (CML) (75). SHP2 has been implicated in transformation by the 
Bcr/Abl oncogene, since mutation of a Gab2 recruitment site (Y177) inhibits trafficking of 
Gab2 and subsequent SHP2 and PI3K recruitment and activation (76). This result is in 
agreement with previous data suggesting the direct association of Bcr/Abl with SHP2, with 
each protein acting upon the other as substrates (77).  
2.5.3) SHP2 in solid tumors 
 
The last decade of research into SHP2 has seen a growing appreciation for its role in cancer of 
different forms (26,78). As in the case of adult leukemias, mutation of SHP2 is quite rare in 
most solid neoplasia. More often, hyperactivation of the phosphatase is produced by 
overexpression of SHP2 itself or by overexpression of an activating molecule. An example of 
the latter phenomenon occurs following stomach infection with the ulcer-causing bacterium 
Helicobacter pylori. One of its most prominent virulence factors is the CagA protein, a 
scaffolding molecule that becomes phosphorylated on several tyrosine residues. 
Phosphorylation promotes the recruitment and activation of SHP2, and this complex enhances 
gastric carcinoma cell signaling (79).  
In lung cancer, a correlation between SHP2 expression and lymph node metastasis has 
been identified (80). The association of SHP2 with lung cancer is unsurprising due to the 
predominance of EGFR overexpression or mutation in various forms of the disease, which 
would lead to constitutive Ras/MAPK signaling that is further enhanced by SHP2 (81). 
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Some evidence has come to light in recent years that shows SHP2 can act as a tumor 
suppressor, depending on cell context. Hepatocellular carcinoma is the first identified disease 
where clinical data suggest a tumor suppressive function for SHP2. A study of 333 Chinese 
liver cancer patients found a significant overall survival advantage for patients with elevated 
SHP2 expression in the tumor compared with normal tissue (82). These results agreed with 
previous animal-based studies demonstrating a liver-specific deletion of SHP2 enhances 
inflammatory signaling through STAT3, promoting hyperplastic growth in the liver (83). In all, 
these results demonstrate that the role of SHP2 in disease is context-dependent, and whether 
it acts as a tumor suppressor or a proto-oncogene depends on the pathways that are naturally 
prevalent in the organ or tumor of interest (26). 
2.5.3.1) SHP2 in breast cancer  
 
The role of SHP2 in breast cancer biology has been studied extensively in the last decade. SHP2 
promotes mitogenesis, cell survival, and mesenchymal phenotypes in breast cancer cell culture 
experiments, and these effects correlate with overexpression of SHP2 protein (28,84). Various 
mouse models have demonstrated reliance on SHP2 for the maintenance and progression of 
breast tumors, especially in the context of HER2 dependence (27).  
Aside from in vitro phenotype of breast cancer cells, the most important finding 
regarding SHP2 in breast cancer relates to clinical samples. Three studies have been published 
exploring this phenomenon. The first of these studies collected 83 invasive ductal carcinoma 
patient samples and found elevated SHP2 expression levels (assessed by 
immunohistochemistry) in 73%; elevated SHP2 levels correlated with both HER2 positivity 
(79% of HER2-positive tumors overexpressed SHP2) and lymph node metastasis (37/39 node-
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positive tumors overexpressed SHP2) (28). Aceto, et al noted approximately 91% of breast 
tumors showed high expression of SHP2, though they were unable to consistently find 
differences between normal and tumor expression levels. Still, a greater proportion of patients 
with a SHP2 gene expression signature (i.e., genes that are downregulated in breast cancer 
cells when SHP2 expression is inhibited through RNA interference) showed poor prognosis, 
especially when breast cancer had progressed to invasive ductal carcinoma (27). 
The most recent patient study of SHP2 in breast cancer used the highest number of 
patient samples (n=1041). Of these, 651 (46%) showed positive expression of SHP2. 
Significantly, SHP2 positivity correlated with significantly-lower overall survival of patients, 
leading to a 45.8% increased risk of mortality over the course of the study (85). In all, these 




3) HER2 Stabilizes EGFR and Itself by Altering Autophosphorylation 
Patterns in a Manner That Overcomes Regulatory Mechanisms and 
Promotes Proliferative and Transformation Signaling 
3.1) Abstract 
One of the causes of breast cancer is overexpression of the human epidermal growth factor 
receptor 2 (HER2). Enhanced receptor autophosphorylation and resistance to activation-induced 
down regulation have been suggested as mechanisms for HER2-induced sustained signaling and 
cell transformation. However, the molecular mechanisms underlying these possibilities remain 
incompletely understood. In the current report, we present evidence that show that HER2 
overexpression does not lead to receptor hyper-autophosphorylation, but alters patterns in a 
manner that favors receptor stability and sustained signaling. Specifically, HER2 overexpression 
blocks EGFR tyrosine phosphorylation on Y1045 and Y1068, the known docking sites of c-Cbl and 
Grb2, respectively, while promoting phosphorylation on Y1173, the known docking site of the Gab 
adaptor proteins and phospholipase C gamma (PLC). Under these conditions, HER2 itself is 
phosphorylated on Y1221/1222, with no known role, and on Y1248 that corresponds to Y1173 of 
EGFR. Interestingly, suppressed EGFR autophosphorylation on the Grb2 and c-Cbl binding sites 
correlated with receptor stability and sustained signaling, suggesting that HER2 accomplishes these 
tasks by altering autophosphorylation patterns. In conformity with these findings, mutation of the 
Grb2 binding site on EGFR (Y1068F-EGFR) conferred resistance to ligand-induced degradation 
which in turn induced sustained signaling, and increased cell proliferation and transformation. 
These findings suggest that the Grb2 binding site on EGFR is redundant for signaling, but critical for 
receptor regulation. On the other hand, mutation of the putative Grb2 binding site in HER2 (Y1139) 
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did not affect stability, signaling or transformation, suggesting that Y1139 in HER2 may not serve as 
a Grb2 binding site. In agreement with the role of EGFR in HER2 signaling, inhibition of EGFR 
expression reduced HER2-induced anchorage-independent growth and tumorigenesis. These 
results imply that complementing HER2-targeted therapies with anti-EGFR drugs may be beneficial 
in HER2-positive breast cancer. 
3.2) Introduction 
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) comprises 
four members that include EGFR1-4. The human counterparts are called HER1-4, also referred to as 
ErbB1-4 (86-88). All members are composed of an extracellular ligand-binding region, a 
transmembrane region, and a cytoplasmic region containing a Tyr kinase domain (except HER3) 
and Tyr autophosphorylation sites. Three of the family members, except HER2 (89), are activated 
by ligand binding (EGF, TGF, heregulin, amphiregulin and heparin binding EGF) to the 
extracellular region, while HER2 is a constitutively active protein. Because EGFR1 is commonly 
known as EGFR and EGFR2 as HER2, we have used these abbreviations throughout this manuscript 
hereinafter. 
The x-ray crystallographic structure of the EGFR ectodomain shows that the dimerization arm 
is autoinhibited in the resting state by intramolecular interaction between domains 2 and 4, but 
EGF binding induces conformational changes that relieve the dimerization arm, leading to homo- or 
heterodimerization  (90-92). On the other hand, no interactions between domains 2 and 4 were 
observed in the HER2 ectodomain (89). As a result, HER2 can readily heterodimerize with ligand-
activated family members or homodimerize with itself, especially under conditions of 
overexpression, a commonly encountered genetic abnormality particularly in breast cancer (93-
31 
96). It might be this structural property of HER2 that allows it to act as the preferred partner of 
heterodimerization with the other family members.  
In the EGFR family, ligand activation leads to receptor dimerization and autophosphorylation 
of tyrosine residues in the C-terminal region that provide docking sites for Src homology 2 (SH2) or 
phosphotyrosine binding (PTB) domain-containing signaling molecules (97). These interactions 
lead to recruitment of adaptor proteins such as Grb2, Gab1/2 and Shc that mediate further 
interactions, translocation of enzymes to substrate micro domains such as PI3K and the Ras 
nucleotide exchange factor SOS, binding of regulatory proteins such as c-Cbl and RasGAP, and in 
some instances, activation of enzymes such as SHP1 and SHP2 (98-101). The formation of 
multiprotein signaling complexes at the level of the receptor accomplishes two major tasks - 
activation of mitogenic and cell survival signaling pathways, and down regulation of receptor 
activity (49,102-107).   
Ligand binding to a receptor tyrosine kinase (RTK) induces endocytosis, ubiquitinylation and 
degradation, which is considered to be the primary mechanism of regulation. The EGFR family is 
also regulated by this mechanism (108-111), but HER2 seems to be a poorly regulated RTK even 
when it is heterodimerized with the other family members (112,113). Although the ability of HER2 
to overcome regulatory mechanisms is well recognized, the molecular mechanisms that enable 
HER2 to accomplish these tasks have remained unexplored. In the current report, we present 
evidence that show that HER2 overcomes regulatory mechanism by altering autophosphorylation 
patterns both on itself and the heterodimerized EGFR in a manner that favors downstream 
signaling and disfavors ligand-induced down regulation. By doing so, HER2 exploits the EGFR to 
enhance its signaling, transformation, and tumorigenic potency.  
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3.3) Materials and Methods 
3.3.1) Cells, cell culture and reagents  
The cells used in this study, the MCF10A breast epithelial, and the BT20 and the Skbr-3 breast 
cancer cell lines, were purchased from ATCC, while the mouse embryo fibroblasts (MEFs) were a 
gift from Dr. Steven Frisch (West Virginia University). The MEFs and the BT20 cells were grown in 
regular Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal calf serum, 
while the MCF10A were grown in DMEM supplemented with the indicated ingredients (10 g/ml 
recombinant human insulin, 20 ng/ml EGF (PeproTech), 0.5 g/ml hydrocortisone, 100 ng/ml 
cholera toxin (Sigma) and 5% horse serum), as described previously (114). All cell lines were 
grown in a 37°C incubator with 5% CO2 supply. The anti-EGFR polyclonal antibody (E1157), and the 
anti-FLAG (F3165) and the anti-β-actin (A5441) monoclonal antibodies were purchased from 
Sigma-Aldrich, while the anti-HER2 (610162) monoclonal antibody was from Pharmagen. 
Antibodies to phospho-ERK1/2 (9101S), phospho-Akt (9271S), phospho-EGFR (2234, 2237, 4404, 
4407) and phospho-HER2 (2243, 2244) were from Cell Signaling. The anti-c-CBL antibodies (SC-
170 and SC-1651) and the anti-panERK2 antibody (SC-81457) were bought from Santa Cruz 
Biotechnology. Secondary antibodies conjugated with horseradish peroxidase were from Amersham 
(NA934V and NA931V), and Molecular Probes (A11079). TRITC-labeled EGF was purchased from 
Molecular Probes. 
 
3.3.2) Subcloning, retroviral transduction and production of stable cell lines 
Full-length wild type and mutant HER2 and EGFR proteins were subcloned into the 
REBNA/IRES/GFP retroviral vector as reported previously (115). Recombinant retroviral particles 
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expressing the different HER2 and EGFR proteins were produced by transfection into appropriate 
packaging cells using the FuGENE 6 transfection reagent (Roche). The MCF-10A, the BT20 and the 
MEF cell lines stably expressing the vector and the different EGFR and HER2 proteins were 
produced by infection with the respective retroviruses in the presence of 1µg/ml polybrene 
(Sigma). After incubation in growth medium for approximately 48 hours, cells were treated with 1 
µg/ml blasticidine, the selection antibiotic expressed by the viral vector, to remove non-expressing 
cells. Blasticidine-resistant cell populations were used for the various experiments described in this 
manuscript. 
 
3.3.3) Stable anti-EGFR shRNA expression 
The expression of the EGFR in the HER2 cells derived from the BT20 line was accomplished as 
described by us and others (116). Briefly, double-stranded DNA the codes for anti-EGFR shRNA was 
custom-synthesized (Integrated DNA Technologies) and ligated into the BamHI and EcoRI sites of 
pSIREN-RetroQ-TetP (BD Biosciences, Palo Alto, CA). The targeting oligonucleotide sequence was 5'-
GGAGCTGCCCATGAGAAAT-3'. After packaging in appropriate cells, transient supernatants (after 48 
hours of incubation) were used to infect the BT20-HER2and the Skbr-3 cells. A non-targeting anti-
Luciferase shRNA was used as a control. Non-expressing cells were removed by puromycin 




3.3.4) Preparation of cell lysates, gel electrophoresis and immunostaining analysis 
All cell lysates were prepared in a buffer containing 20 mM Tris-HCl, pH7.2, 150 mM NaCl, 50 mM 
NaF, 1 mM EDTA, 10% glycerol, 1% triton-X-100, 1 mM sodium orthovanadate and a protease 
inhibitor cocktail. Lysates were briefly sonicated to breakdown chromosomal DNA that could 
interfere with protein separation by polyacrylamide gel electrophoresis. After clearing by 
centrifugation at 12,000 rpm for 10 minutes, the lysates were analyzed as described in the 
respective experiments. For separation of proteins, samples were mixed with Laemmli sample 
buffer, denatured by boiling for 10 minutes, and then run on an 8% or 10% denaturing 
polyacrylamide gel. After transfer onto a nitrocellulose membrane and blocking with 3% bovine 
serum albumin, the membranes were stained with primary antibodies overnight at 4oC, washed 3 
times with TBST (Tris-buffered saline containing 0.1% Tween-20) to remove unbound primary 
antibody, stained with secondary antibodies for 1 hour at room temperature, washed 3 times with 
TBST to remove unbound secondary antibody, and finally detected by the chemiluminescence 
method. 
 
3.3.5) Immunoprecipitation studies 
Cells expressing vector alone or WT-HER2 were grown to about 80% density, serum starved 
overnight, and stimulated with 10 ng/ml EGF for desired time points. Lysates prepared from these 
cells were first cleared by centrifugation at 12,000 rpm, and then subjected to immunoprecipitation 
with respective antibodies at 4oC overnight. Precipitates were captured on protein A/G sepharose 
beads by further incubation for 1 hour. Finally, precipitates were washed three times with lysis 
buffer and then eluted by addition of Laemmli sample buffer and boiling for 10 minutes at 100oC. 
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Eluted proteins were separated on polyacrylamide gel electrophoresis and processed for 
immunostaining as described above. 
 
3.3.6) Anchorage-independent growth assay 
Anchorage-independent growth in soft agar was performed in 6 cm cell culture plates. After 
covering bottom of plates with 0.3% agar in the growth medium, approximately 105 cells suspended 
in 3 ml of growth medium and mixed with melted agar to a final concentration of 0.3% were 
immediately poured onto the agar overlay. The agar cultures were transferred to a 37 oC and 5% 
CO2 incubator and maintained for 15 days. The cells were fed with growth medium containing 0.3% 
soft agar twice, and after that, feeding was by replenishing DMEM supplemented with 10% fetal 
bovine serum. Colony formation was monitored by visualization under a microscope, and pictures 
were taken using an Olympus IX71 microscope equipped with DP30BW digital camera.  
 
3.3.7) TRITC-labeled EGF studies 
Cover slips for TRITC-labeled EGF fluorescence studies were prepared as described previously 
(102,117,118). Cells grown on cover slips, serum-starved overnight, pre-chilled at 4oC for 1 hour, 
treated with 10 ng/ml TRITC-labeled EGF for under chilled conditions, washed twice with ice-cold 
serum-free DMEM, replenished with the same serum-free medium and incubated at 37oC for the 
desired time points. Cover slips were then rinsed with room temperature  PBS, fixed in 4% 
paraformaldehyde for 20 minutes, washed 3 times with PBS, and mounted on microscopic slides. 
Pictures were collected using the 40 objectives of Olympus IX-71.  
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3.3.8) In vivo tumorigenesis studies  
Female nude mice were purchased from Jackson laboratories. Approximately 106 MCF-10A-HER2 
cells expressing control or anti-EGFR shRNA were mixed 1:1 with matrigel (BD Biosciences) and 
injected subcutaneously into the rump region of each mouse; three mice were used in each group. 
Tumor growth was monitored by visual observation. When the control shRNA-HER2 mice 
developed tumors that were  1 cm in diameter, all mice were sacrificed, pictures collected, tumors 
retrieved and their weights measured. 
 
3.4) Results 
3.4.1) HER2 overexpression does not lead to receptor hyperphosphorylation 
HER2 is a constitutively active protein (89), a property that may be key to its oncogenicity. We, 
therefore, evaluated receptor autophosphorylation patterns under conditions of HER2 
overexpression. To address this question, it was necessary to ectopically express HER2 so that the 
impact of HER2 overexpression could be compared in the same cell line. Due to the significance of 
HER2 in breast cancer, we have used the non-tumorigenic MCF-10A breast epithelial and the BT20 
breast cancer cell lines both of which express a “normal” amount of EGFR and a very low amount of 
endogenous HER2 and HER3 (119). We have also used the Skbr-3 breast cancer cell line that 
overexpress HER2, but has a “normal” level of EGFR to see if endogenously expressed EGFR and 
HER2 function cooperatively in cell transformation. For mechanistic studies involving mutant EGFR 
and HER2, the mouse embryo fibroblast (MEF) cells were used.   
The pattern of EGF-induced total protein tyrosine phosphorylation in the presence and 
absence of HER2 expression was examined by immunostaining of total cell lysates with anti-pY 
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(anti-phosphotyrosine) antibody. To examine the temporal dynamics of tyrosine phosphorylation, 
time-course EGF stimulation was employed. Surprisingly, the most significant differences were the 
initial hyperphosphorylation of the EGFR in the controls that rapidly declined after 10 minutes, and 
the relatively moderate, but sustained receptor autophosphorylation in the HER2 cells (Fig.S1A and 
B). Reprobing for EGFR showed that it was stabilized in the HER2 cells and rapidly degraded in the 
controls (Fig.S1A and B), which is consistent with previous reports (112,113,120).  Further 
reprobing with anti-HER2 antibody revealed that HER2 was unaffected by ligand stimulation, 
confirming our recent report (119). These results suggest that receptor hyperphosphorylation 
occurs in the absence of HER2, but declines rapidly due to degradation.  
The above findings led us concentrate on impact of HER2 overexpression on receptor 
autophosphorylation. EGFR and heterodimerized HER2 were isolated from cell lysates by 
immunoprecipitation reactions, and their total phosphorylation state was determined by 
immunostaining anti-pY antibody. To exclude differences due to ligand-induced receptor down 
regulation, the first 5 minutes of EGF stimulation was used for these experiments. Input total cell 
lysates used in these experiments had comparable amount of EGFR in all lanes, and similarly 
comparable levels of HER2 in the HER2 cells (Fig.1A). Consistent with the results presented in 
Fig.S1A and B, EGF stimulation induced an enhanced receptor autophosphorylation in the controls, 
but a relatively modest autophosphorylation in the HER2 cells (Fig.1B). Significant receptor 
autophosphorylation also occurred in the HER2 cells in the absence of EGF stimulation, suggesting 
that HER2 can induce basal signaling under conditions of overexpression. Successive reblotting 
showed that EGFR was efficiently precipitated, and the ectopically expressed HER2 was likewise co-
precipitated with EGFR mainly in EGF-stimulation dependent manner. Band density measurements 
from at least three independent experiments showed that EGF-induced total receptor 
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autophosphorylation was lower by approximately 25% in the HER2 cells (Fig.1C). This looked 
paradoxical, but it nevertheless provided a clue as to the occurrence of reduced receptor 
autophosphorylation when HER2 is co-expressed with the EGFR. 
 
3.4.2) HER2 alters autophosphorylation patterns in a manner that confers differential 
interaction 
The unexpected differences in total receptor autophosphorylation between the controls and the 
HER2 cells led us investigate the phosphorylation state of individual autophosphorylation sites in 
both EGFR and HER2 in total cell lysates whose input protein levels are shown in Fig.2A. EGF 
stimulation led to a robust phosphorylation of the EGFR on Y1045 and Y1068, the docking sites of 
c-Cbl and Grb2, respectively, in the controls, but phosphorylation on these sites was significantly 
reduced in the HER2 cells (Fig.2B). In addition, phosphorylation on Y1148, the docking site of the 
Shc proteins, was lower in the HER2 cells, although not as dramatic as the Grb2 and the c-Cbl sites. 
On the other hand, phosphorylation on Y1173, the docking site of Gab1 and PLC, was significantly 
higher in the HER2 cells and lower in the controls. We were also able to determine the state of 
HER2 autophosphorylation on Y1221/1222, which have no corresponding sites in EGFR, and on 
Y1248 that corresponds to Y1173 of EGFR. HER2 was phosphorylated even in the absence of EGF 
stimulation on these sites, which was further enhanced by EGF stimulation. These findings 
demonstrate that EGFR autophosphorylation is enhanced on the Gab1 (which recruits PI3K and 
SHP2) and PLC binding sites, and suppressed on the c-Cbl and the Grb2 binding sites in the 
presence of HER2.  
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The observed differential autophosphorylation pattern could have been due to activation of 
certain phosphotyrosyl phosphatases (PTPs) by HER2. To verify this point, cells were treated with 
the general PTP inhibitor orthovanadate and lysates prepared from them were analyzed in the 
same way as above. Inhibition of PTP activity both in the control and HER2 cells derive from the 
MCF-10A and BT20 lines did not lead to changes in autophosphorylation patterns (Fig.2C and data 
not shown).  Therefore, the reduced total receptor autophosphorylation in the HER2 cells was due 
to altered autophosphorylation induced by HER2.  
Since altered autophosphorylation might lead to differential interaction with downstream 
signaling proteins, immunoprecipitation experiments were conducted to test this possibility. 
Consistent with the autophosphorylation data, the EGF-induced interaction of c-Cbl and Grb2 
proteins with EGFR was elevated in the controls and lowered in the HER2 cells (Fig.2D), while the 
reverse was true for Gab1, p85 (subunit of PI3K) and SHP2. Despite moderate differences in EGFR 
phosphorylation on Y1148 between the control and the HER2 cells, the interaction of the Shc 
proteins was significantly lower in the HER2 cells. This outcome might reflect additive effects - 
directly due to reduced pY1148 and indirectly due to reduced pY1068 (Grb2-mediated); note that 
Shc proteins can make direct and indirect (through Grb2) interactions with activated receptors. 
Therefore, HER2 promotes altered autophosphorylation that leads to differential interaction with 
signaling and regulatory proteins. Although we have not directly tested HER2 autophosphorylation 
at the corresponding Grb2 (Y1139) and c-Cbl (Y1112) binding sites due to lack of specific 
antibodies, the low level of Grb2 and c-Cbl interaction in the HER2 cells suggests that HER2 may not 
be phosphorylated on these sites.   
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3.4.3) c-Cbl is unable to interact with the EGFR:HER2 heterodimer, leading to reduced 
ubiquitinylation  
A previous study has shown that controlled EGFR:HER2 heterodimers tend to exclude c-Cbl 
interaction (121), but the mechanism was not known. The results presented in Figs.2B and C 
demonstrated that autophosphorylation of the EGFR and possibly HER2 on the c-Cbl and the major 
Grb2 binding sites is very low in the presence of HER2, eliminating the direct and indirect 
interaction of c-Cbl. This may be the mechanism by which HER2 excludes c-Cbl. Consistent with this 
notion EGFR coprecipitated with c-Cbl efficiently in the controls, and poorly in the HER2 cells 
(Fig.3A and B). Furthermore, HER2 was undetectable in c-Cbl immunoprecipitates, confirming that 
c-Cbl does not interact with EGFR-HER2 heterodimers. Reprobing with anti-c-Cbl antibody showed 
that the amount of c-Cbl was comparable in all lanes. These results, together with the findings in 
Fig.2B and D, show that the mechanism by which HER2 excludes the interaction of c-Cbl is through 
suppression of autophosphorylation on the direct and indirect c-Cbl binding sites.  
Based on the results in Fig.3A and B, it was reasoned that exclusion of c-Cbl interaction by 
HER2 could lead to inhibition of ubiquitinylation. Consistent with this assumption, EGFR in the 
control cells was highly ubiquitinylated, but less so in the HER2 cells despite the presence of 
comparable amount of receptor molecules in all lanes (Fig.3C and D). Therefore, the mechanism by 
which HER2 protects itself as well as EGFR from ligand-induced ubiquitinylation and degradation is 
by regulating the interaction of c-Cbl through altering autophosphorylation patterns.  
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3.4.4) HER2-induced inhibition of Grb2-binding site autophosphorylation does not 
perturb signaling 
Inhibition of EGFR autophosphorylation on Y1068 in the HER2 cells was unexpected as this site 
was previously reported to promote Ras activation by acting as the major Grb2-SOS complex 
docking site. We therefore tested the state of EGF-induced downstream signaling under our 
experimental conditions. Because HER2 is known to induce sustained signaling, these experiments 
were conducted in a time course fashion. ERK1/2 and Akt activation was sustained in the HER2 
cells and short-lived in the controls, suggesting the existence of an inverse relationship with 
elevated phosphorylation of the Grb2 binding site in EGFR (Fig.4A and D). In agreement with the 
dynamics of EGF-induced EGFR degradation (Fig.S1 and (119)), initial ERK1/2 and Akt activation 
(first 10 minutes) was comparable in both the controls and the HER2 cells, but rapidly declined in 
the former and sustained in the latter. It was also possible to discern a revamping pattern in 
ERK1/2 and Akt activation in the HER2 cells after 2 hours, reflecting receptor recycling as reported 
by us recently (119). As compared to the controls, the HER2 cells showed basal ERK1/2 and Akt 
activation, suggesting that HER2 alone can induce a low level of constitutive signaling. Anti-
panERK2 immunostaining showed that the amount of total protein loaded to each lane was 
comparable. Band density measurements (Fig.4B, C, E and F) confirmed that ERK1/2 and Akt 
activation in both cells were comparable at the 10 minutes time point, but rapidly declined in the 
controls to approximately 20% of the initial value, and never fell below 50% of the initial value in 
the HER2 cells. Therefore, the low level of Grb2 binding-site autophosphorylation in the presence of 
HER2 does not perturb signaling.  
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3.4.5) Y1068F-EGFR induces sustained signaling compared to the wild-type counterpart   
The induction of sustained signaling by HER2 while suppressing Grb2 binding required direct 
testing. Site-directed mutagenesis was used to replace Y1068 in EGFR and Y1139 in HER2 with Phe, 
which were referred to as Y1068F-EGFR and Y1139F-HER2, respectively. The vector, the wild-type 
and the mutant proteins (FLAG-tagged at the c-terminus) were expressed by retrovirus 
transduction in the mouse embryo fibroblast (MEF) cells that have very low-to-undetectable level 
of endogenous EGFR and HER2. Time-course EGF stimulation studies were conducted to examine 
the impact of the Grb2 binding-site mutation on the signaling and dynamics of ligand-induced 
receptor regulation. Expression of both WT-EGFR and Y1068F-EGFR led to an enhanced ERK1/2 
and Akt activation initially, but it was short lived in the WT-EGFR and sustained in the Y1068F-
EGFR cells (Fig.5A). Anti-EGFR immunostaining revealed that Y1068F-EGFR was resistant to EGF-
induced degradation, but the wild type counterpart was not. With regard to HER2, both WT-HER2 
and Y1139F-HER2 were able to induce sustained ERK1/2 and Akt activation, which was slightly 
enhanced by EGF stimulation (Fig.5B). Reprobing for HER2 showed that both the WT-HER2 and the 
Y1139F-HER2 proteins were unaffected by EGF stimulation. Hence, Y1139, the putative Grb2 
binding site in HER2, does not seem to play any significant role either in mediating signaling or 
receptor down regulation.     
The above results led us determine the state of Grb2, SOS and c-Cbl interaction with the wild-
type and the mutant EGFR proteins by immunoprecipitation experiments. As expected, mutation of 
the Grb2 binding site significantly reduced the interaction of Grb2 and SOS with EGFR (Fig.5C). The 
interaction of c-Cbl was very low in the Y1068F-EGFR cells regardless of the presence of intact 
Y1045, suggesting that the Grb2-mediated (indirect) interaction plays a major role in recruiting c-
Cbl to EGFR. Consistent with loss of c-Cbl interaction, Y1068F-EGFR was less ubiquitinylated than 
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the wild type counterpart. Reprobing for EGFR showed that comparable amount of both WT-EGFR 
and Y1068F-EGFR were present in all lanes. These findings suggest that Grb2 mediates receptor 
ubiquitinylation and degradation by acting as an adaptor to c-Cbl. In support of our conclusion, 
previous reports have also shown that Grb2 mediates receptor degradation by recruiting c-Cbl 
(122,123). Therefore, HER2-induced suppression of EGFR autophosphorylation at the Grb2 binding 
site protects EGFR from ligand-induced degradation, and affords the EGFR with the ability to induce 
sustained signaling. 
 
3.4.6) EGF-induced Y1068F-EGFR trafficking resembles that of WT-EGFR in presence of 
HER2 
The resistance of Y1068F-EGFR to ligand-induced degradation was very similar to that induced by 
HER2 coexpression (Fig.S1A and B, (119)). To further compare this possibility, the dynamics of 
ligand-induced EGFR trafficking was studied by fluorescence microscopy in MEF cells ectopically 
expressing WT-EGFR or Y1068F-EGFR, and in BT20 and in MCF-10A cells expressing vector alone 
or HER2. Cells were treated with TRITC-EGF at 4oC to initiate binding without inducing 
internalization, hence allowing a synchronized endocytosis and processing when cells are 
transferred back to 37oC after removal of unbound EGF (118). Both WT-EGFR and Y1068F-EGFR 
expressed in MEFs were at the plasma membrane when cells were fixed immediately, but 
incubation at 37oC led to internalization within 10 minutes (Fig.5D). Similarly, EGFR in both the 
control and the HER2 cells derived from the BT20 and the MCF-10A lines was at the plasma 
membrane at the zero time point, but was readily internalized within 10 minutes of incubation at 
37oC as depicted by speckled cytoplasmic distribution (Fig.5E and F). Upon further incubation, 
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ectopically expressed WT-EGFR in the MEFs, and endogenous EGFR in the control BT20 and MCF-
10A cells was sorted to the perinuclear region and decayed gradually. On the other hand, Y1068F-
EGFR in the MEFs behaved like WT-EGFR in the HER2 cells; in these cells, most of the EGFR signal 
was sorted to one side of the nucleus with gradual outward extension and minimal decline. 
Therefore, the dynamics of EGF-induced Y1068F-EGFR processing resembles HER2 
overexpression-induced EGFR recycling.  
 
3.4.7) Y1068F-EGFR is more transforming when compared to the wild-type counterpart 
The results presented in Fig.5 demonstrated that the Y1068F-EGFR is more signaling competent 
than the wild type counterpart, while both the wild type and the mutant HER2 proteins are equally 
competent. The biological significance of these observations was further tested by evaluating 
changes in cell morphology, growth and transformation. In the absence of EGF stimulation, neither 
the wild-type nor the mutant EGFR protein induced any appreciable change in cell morphology, 
proliferation or transformation (data not shown). In the presence of EGF (2 ng/ml), however, the 
distinctive properties of the two proteins became apparent. MEFs expressing the Y1068F-EGFR 
acquired an elongated and refractive morphology in 2D (Fig.S2A), an increased proliferative 
potential (Fig.6A, left) and ability to form colonies in soft agar (Fig.6B). On the other hand, the mere 
expression of both WT-HER2 and Y1139F-HER2 proteins induced morphological changes 
characterized by an interspersed and refractive appearance that forms foci-like structures de novo 
(Fig.S2B). In addition, both HER2 proteins were capable of inducing increased cell proliferation 
(Fig.6A, right), and robust colony formation in soft agar (Fig.6C). These results suggest that 
Y1068F-EGFR is superior in inducing cell growth and transformation than its wild type 
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counterpart, which in turn suggests that inhibition of EGFR phosphorylation on Y1068 by HER2 
confers signaling and transformation efficiency. Furthermore, these data show that mutation of 
Y1139 in HER2, the putative Grb2-binding autophosphorylation site, does not perturb transforming 
ability, suggesting that Y1139 in HER2 may not play any significant role. Overall, the superiority of 
HER2 in inducing enhanced cell growth and transformation suggests that it has additional effects 
other than altering autophosphorylation patterns.  
To further corroborate the role of EGFR in HER2-induced transformation, its expression was 
silenced in the Skbr-3 breast cancer cell line that naturally has amplified HER2 gene and normal 
level of EGFR. Silencing EGFR in these cells reduced the size of HER2-induced colony growth in 3D 
without significantly affecting colony number (Fig.6D-F). These results confirm the ectopic HER2 
overexpression data in the BT20 and the MCF-10A cells that EGFR contributes significantly to 
HER2-induced signaling and transformation. 
3.4.8) HER2 exploits the EGFR to enhance its tumorigenic potential 
The results so far described demonstrate that HER2 alters autophosphorylation patterns to confer 
resistance to ligand-induced degradation and to ultimately enhance cooperative signaling and 
transformational capacity. Finally, we sought to test whether or not the normally-expressed EGFR 
contributes significantly to HER2-iduced tumorigenesis in vivo.  
The BT20 HER2 cells expressing control or anti-EGFR shRNA were injected subcutaneously 
into nude mice, and tumor formation was monitored by visual observation. The HER2 cells in which 
EGFR expression was silenced formed smaller and rounded tumors, while those that co-expressed 
EGFR with HER2 formed larger and irregular ones (Fig.6G). Pictures of isolated tumors further 
showed differences in tumor size and shape (Fig.6H). Measuring tumor weight confirmed that 
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blocking EGFR expression in the HER2 cells reduced tumor burden by approximately 3.5 fold 
(Fig.6I). Therefore, HER2-induced tumorigenesis is dependent on EGFR, suggesting that the 
normally-expressed EGFR may potentiate the oncogenic property of HER2 in HER2-positive breast 
cancer. In other words, HER2 is capable of mustering signaling efficiency from the normally 
expressed family members by promoting their stability through altering autophosphorylation 
patterns. 
3.5) Discussion 
HER2 is an oncogenic transmembrane tyrosine kinase that induces cell transformation and 
tumorigenesis when it is overexpressed in tissues. Its overexpression, primarily due to gene 
amplification, is one of the major causes of breast cancer. HER2 is a constitutively active protein 
(89) with intrinsically low tyrosine kinase activity (124,125). This property of HER2 may be 
responsible for its ability to escape activation-induced down regulation, one of the suggested 
mechanisms for its oncogenesis.  We thus investigated the effect of HER2 overexpression on 
receptor autophosphorylation and its impact on protein stability, downstream signaling, and cell 
transformation. Furthermore, we have presented data that show that EGFR contributes 
significantly to HER2-induced tumorigenesis in xenograft mice models. 
We have shown that HER2 overexpression leads neither to increased overall cellular tyrosine 
phosphorylation nor to receptor hyper-autophosphorylation. To the contrary, receptor hyper-
autophosphorylation occurs in the absence of HER2 (Fig.1B and C). These data were indicative of 
the occurrence of reduced receptor autophosphorylation when EGFR and HER2 heterodimerize. 
Analyzing specific autophosphorylation sites demonstrated that phosphorylation of the EGFR on 
Y1045 and Y1068 (the docking sites of c-Cbl and Grb2, respectively) was suppressed in the absence 
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of HER2 while the opposite was true for Y1173 of EGFR and for Y1221/1222 and Y1248 of HER2 
(Fig.2B). Although we have not determined phosphorylation of the putative c-Cbl and Grb2 docking 
sites (Y1112 and Y1139, respectively) in HER2 due to lack of specific antibodies, the modest overall 
autophosphorylation suggests that phosphorylation on these sites may not occur.  
In agreement with the autophosphorylation data, c-Cbl and Grb2 interact strongly with EGFR 
homodimers, and poorly with EGFR:HER2 heterodimers (Fig.2D). The poor interaction of c-Cbl and 
Grb2 with HER2-containing complexes provides further evidence that HER2 may not be 
phosphorylated on Y1112 and Y1139. The low level of c-Cbl binding-site autophosphorylation in 
the presence of HER2 lends mechanistic support to the previous observation that EGFR:HER2 
complexes tend exclude c-Cbl binding (121). In addition to its signaling role, Grb2 is known to 
mediate the interaction of c-Cbl with activated receptor molecules (123). Hence, the low level of 
Y1068 phosphorylation in the presence of HER2 blocks the indirect interaction of c-Cbl (Fig.2D, and 
Fig.3A and B), which in turn leads to the low level of receptor ubiquitinylation (Fig.3C and D). 
Therefore, the mechanism by which HER2 confers receptor stability is through altered 
autophosphorylation. However, our results cannot exclude the existence of other as yet 
unidentified ubiquitin ligases excluded by HER2 that may contribute to receptor resistance to 
ligand-induced degradation.  
While blocking autophosphorylation on the c-Cbl and the Grb2 binding sites, HER2 promotes 
EGFR phosphorylation on Y1173 and its own phosphorylation on Y1248 and Y1221/1222 (Fig.2B). 
Phosphorylated Y1173 of EGFR and Y1248 of HER2 are known docking sites for the Gab1/Gab2 
adaptor proteins (126,127). Consistent with the phosphorylation data, the interaction of Gab1 was 
elevated in the HER2 cells, and lowered in the control cells (Fig.2D). Upon binding to RTKs and 
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phosphorylation on multiple tyrosine residues, Gab1 serves as a docking platform for several 
signaling proteins, leading to formation of multiprotein complexes. Because EGFR and HER2 lack 
tyrosine residues that mediate direct PI3K binding, the interaction of PI3K with the EGFR:HER2 
complexes is most probably through Gab1. Previous reports suggest that SHP2, the known positive 
effector of EGFR and HER2 signaling, interacts with EGFR and HER2 through Gab1 (128,129). 
Therefore, the increased interaction of SHP2 with EGFR and HER2 complexes may as well be 
through Gab1.  
HER2 does not significantly influence the state of EGFR phosphorylation on Y1148, the 
docking site of the Shc adaptor proteins, but relatively less Shc proteins bind to EGFR:HER2 
heterodimers. The reduced Shc interaction may be related to low Grb2 binding in the HER2 cells; 
note that Shc proteins are known to also make indirect interaction with RTKs through 
Grb2(130,131). Hence, the low level of EGFR autophosphorylation on Y1068 in the presence of 
HER2 reduces the interaction of Grb2 directly and that of c-Cbl and Shc proteins indirectly. A 
previous phosphoproteomic study suggested that Y1222 in HER2 may mediate Shc binding (132), 
but our results demonstrate very low binding of Shc proteins regardless of enhanced HER2 
phosporylation on Y1221/1222. It is possible that HER2 molecules behave differently inside (this 
report) and outside (132) the cell. Nonetheless, the presence of HER2 autophosphorylation on 
these sites suggests that they may contribute to the direct and indirect binding of other signaling 
proteins. It will be interesting to address these points in future studies. Overall, our results show 
that HER2 alters autophosphorylation patterns of the EGFR and of itself, favoring Gab1, p85 (PI3K) 
and SHP2, and disfavoring c-Cbl and Grb2 interactions.  
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The mechanism by which HER2 alters the autophosphorylation pattern within the 
heterodimer is unknown at this stage. Recent structural and modeling studies on receptor tyrosine 
kinases suggest that the kinase domains of dimerized receptor molecules form asymmetric dimmer 
that has a positive allosteric effect on kinase activation (133,134). This has been demonstrated for 
EGFR homodimers, FGFR1 homodimers, FGFR2 homodimers, and HER2 and HER4 heterodimers. 
The occurrence of such kinase domain asymmetry in the EGFR:HER2 heterodimer has not been 
demonstrated, but it is thought to be a common phenomenon (135). It is possible that subtle 
structural arrangements in the EGFR:HER2 heterodimer hinder phosphorylation on the direct and 
indirect c-Cbl interaction sites, while promoting on those sites that mediate downstream signaling. 
A second possibility is that the kinase domain of HER2 may have the ability to discriminate among 
autophosphorylation sites, leading to distinctive autophosphorylation. A third possibility might be 
that the intrinsically low tyrosine kinase activity of HER2 (124,125) may lead to phosphorylation of 
some, but not all sites on EGFR and HER2 itself, leading to differential autophosphorylation 
patterns. Future structural studies on EGFR:HER2 heterodimers may be needed to delineate 
between these possibilities.  
Because HER2 promotes the interaction of the SHP2 tyrosine phosphatase, the known positive 
effector of RTK signaling, including EGFR and HER2, one may also argue that HER2 suppresses 
autophosphorylation on the c-Cbl and Grb2 binding sites indirectly by facilitating SHP2-mediated 
dephosphorylation. However, this possibility is unlikely since SHP2 is a highly selective 
phosphatase, targeting only RasGAP docking sites in EGFR (49) and HER2 (25). The involvement of 
other PTPs also is unlikely since treatment with orthovanadate, the general PTP inhibitor, did not 
lead to differences in the autophosphorylation patterns (Fig.2C). In addition, the occurrence of this 
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event in less than 2 minutes of EGF stimulation strengthens the notion that HER2 does not act 
through tyrosine phosphatases to modulate autophosphorylation patterns.  
One of the most unexpected findings was the induction of sustained signaling by the EGFR 
mutant lacking the Grb2 binding site (Y1068F-EGFR) (Fig.5A). Analysis of EGF-induced receptor 
regulation has revealed that Y1068F-EGFR is relatively resistant to degradation. 
Immunoprecipitation studies further revealed that EGFR lacking the Grb2 binding site interacts 
poorly with c-Cbl and is least ubiquitinylated (Fig.5C), explaining the observed resistance to ligand-
induced degradation. A further layer of evidence came from fluorescent-tagged EGF stimulation 
studies which demonstrated that Y1068-EGFR is efficiently internalized upon EGF stimulation, but 
not degraded. Hence, the sustained signaling efficiency of the Y1068F-EGFR is related to its 
resistance to EGF-induced degradation. Comparison of ligand-induced Y1068F-EGFR sorting with 
HER2-induced sorting of endogenous EGFR (compare Fig.5D with E and F) showed a striking 
similarity, providing experimental evidence for the HER2-induced suppression of EGFR 
autophosphorylation on Y1068 conferring resistance to ligand-induced degradation. The increased 
cell proliferation and transformation induced by the Y1068F-EGFR (Fig.6A and B) provide further 
support for this role of HER2.  
The commonly-held notion is that Grb2 mediates Ras activation by acting as an adaptor to the 
nucleotide exchange factor SOS to bind to activated receptor tyrosine kinases at the plasma 
membrane where functional Ras resides. The finding that HER2 efficiently activates the Ras-ERK 
signaling pathway while suppressing Grb2 interaction contrasts with this notion. The ability of the 
Y1068F-EGFR to induce enhanced and sustained ERK1/2 and Akt activation, while having 
significantly reduced Grb2-SOS binding confirms the current findings. The corresponding HER2 
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mutant (Y1139F-HER2) that lacks Grb2 binding site also signals as efficiently as the wild-type 
counterpart. Therefore, interaction of SOS with activated RTKs through Grb2 to activate Ras may be 
redundant or dispensable. In fact, the current data suggest that the major role of Grb2 bound to 
pY1068-EGFR is to mediate a receptor regulatory loop by coordinating the interaction of c-Cbl. A 
recent study suggested that the ERM proteins (ezrin, radixin, moesin) may play critical role in 
recruiting SOS to Ras (136), which may also be functional in HER2 signaling. Future studies are 
needed to further elucidate how HER2 activates the Ras-ERK signaling pathway without utilizing 
Grb2.  
Conferring receptor resistance to activation-induced down regulation through modulation of 
receptor autophosphorylation patterns seems to be the mechanism for HER2 in promoting 
sustained signaling and cell transformation. The results presented in the current report (Fig.6D-I) 
reveal that maximal transformation and tumorigenesis by HER2 was dependent on EGFR. Loss of 
EGFR expression abolished HER2-induced anchorage-independent growth by the HER2 amplified 
breast cancer cell line. Furthermore, the enhanced tumor growth induced by HER2 overexpression 
in the BT20 breast cancer cell line was significantly suppressed, suggesting that HER2 exploits the 
normally expressed EGFR to maximize its oncogenicity. Based on 3H-thymidine-incorporation 
experiments (137), it was previously suggested that EGFR is not required for HER2-induced cell 
proliferation which is in contrast to our findings. It may be necessary to determine the significance 
of EGFR in HER2-induced transformation using transformation and in vivo studies in the future. 
Nonetheless, the implication of our findings is that complementing HER2-targeted therapies with 
anti-EGFR drugs may be beneficial in HER2-positive breast cancer as also evidenced by recent 
clinical trials where the dual tyrosine kinase inhibitor lapatinib was demonstrated to provide 
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clinically beneficial results when administered in combination with anti-HER2 drugs such as 
herceptin (138).  
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3.7) Figure Legends 
Figure 1: Analysis of EGF-induced receptor autophosphorylation.  The control and the HER2 cells 
derived from the MCF-10A and the BT20 lines were serum starved overnight and then stimulated 
with EGF (10 ng/ml) for 2 minutes, 5 minutes or left unstimulated. A) Input total cell lysate analysis 
for EGFR and HER2 in the MCF-10A breast epithelial and in the BT20 breast cancer cell lines. HER2 
was expressed in both cells by retrovirus-mediated transduction. The expression of EGFR in all 
lanes and HER2 in the corresponding lanes was comparable. B) EGFR was immunoprecipitated 
from the total cell lysates shown in A, and then analyzed for total autophosphorylation by 
immunostaining with anti-pY antibody. Reblotting with anti-EGFR and anti-HER2 antibodies 
showed that EGFR was successfully precipitated, and HER2 was likewise co-precipitated in the 
expected lanes. C) Band density measurement of anti-pY blots of EGFR in the controls, and EGFR 
and HER2 heterodimers in the HER2 cells. The results shown were mean  S.D. (standard 
deviation) taken from three independent experiments. 
 
Figure 2: Analysis of specific autophosphorylation and interaction. The control and the HER2 cells 
were serum starved overnight and then stimulated with EGF (10 ng/ml) for the indicated time 
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points. A) Input total cell lysate analysis for EGFR, HER2, Gab1, c-Cbl, p85 (PI3K), SHP2, Shc, Grb2 
and -actin (loading control). B) Analysis of individual autophosphorylation sites in EGFR and 
HER2 using phospho-specific antibodies. In this study, four EGFR and three HER2 
autophosphorylation sites were analyzed. C) Effect of PTP inhibition on receptor 
autophosphorylation patter. Cells were treated with 1 mM orthovanadate for 30 minutes prior to 
EGF stimulation. Lysates prepared from these cells were analyzed for EGFR and HER2 
autophosphorylation as shown. D) Immunoprecipitation and immunostaining analysis of c-Cbl, 
Grb2, Shc, Gab1, p85 (PI3K) and SHP2 interaction with EGFR and EGFR:HER2. Note that the 
interaction of Grb2 and Shc was higher in the control cells and lower in the HER2 cells, and the 
opposite was true for Gab1, p85 (PI3K) and SHP2. 
 
Figure 3: Analysis of EGFR and HER2 coprecipitation with c-Cbl in the MCF-10A (A) and BT20 (B) 
cell lines. The control and the HER2 cells were serum starved overnight and then stimulated with 
EGF (10 ng/ml) for the indicated time points. Lysates prepared from these cells were subjected to 
anti-Cbl immunoprecipitation, and then to immunostaining with the indicated antibodies. State of 
receptor ubiquitinylation (top), HER2and EGFR coprecipitation (middle and bottom, respectively) 
were analyzed by immunostaining with specific antibodies. Data from the MCF-10A is shown in C 
while from the BT20 in D.  
 
Figure 4: Impact of HER2 expression on signaling. As compared to the controls, expression of HER2 
led to an enhanced and sustained ERK1/2 and Akt activation in both the MCF-10A (A) and BT20 (D) 
lines. Band density analysis of ERK1/2 and Akt activation in the MCF-10A- (B and C) and BT20- (E 
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and F) derived lines showed short-lived signaling in the controls and sustained signaling with slight 
decline and revamp in the HER2 cells. Basal pERK1/2 and pAkt activation levels (no EGF 
stimulation) in the controls were used as reference to calculate “fold over basal”. The results shown 
are averages of three independent experiments  S.D. (standard deviation).  
 
Figure 5: Mutation of the Grb2 binding site in EGFR and HER2 does not perturb signaling. A) 
Vector, WT-EGFR or Y1068F-EGFR were expressed in the mouse embryo fibroblast (MEF) cells by 
retroviral transduction, and their impact on EGF-induced ERK1/2 and Akt activation was analyzed 
by immunostaining with specific antibodies. Anti-EGFR immunostaining showed that the 
expression of both EGFR proteins was comparable. Note also that Y1068F-EGFR is resistant to EGF-
induced degradation. B) Similarly, the vector and the WT-HER2 and the Y1139F-HER2 proteins 
were expressed in MEFs and analyzed for ERK1/2 and Akt activation and HER2 expression. Note 
that both WT-HER2 and Y1139F-HER2 induce constitutive signaling, and their stability was 
unaffected by EGF stimulation. C) Interaction of SOS, Grb2 and c-Cbl with EGFR proteins and state 
EGFR ubiquitinylation were analyzed by immunoprecipitation with anti-FLAG and immunostaining 
with the indicated antibodies. D) Dynamics of EGF-induced WT-EGFR and Y1068F-EGFR processing 
in MEFs. Also shown in E and F are dynamics of EGF-induced EGFR (endogenous) processing in the 
MCF-10A  and BT20 lines, respectively.  For fluorescence studies, cells were serum-starved 
overnight, chilled at 4oC for 1 hour, treated with 10 ng/ml TRITC-labeled EGF at 4oC for 1 hour, 
transferred to 37oC and incubated for the indicated time points. Preparation of coverslips and 
picture collection was as described in the materials and methods.   
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Figure 6: A) Impact of EGFR (left) and HER2 (right) expression on cell proliferation was 
determined by counting cells in 10 random 4x objective fields and then averaging. The results 
shown are mean  S.D. (standard deviation) of three independent experiments. B) Expression of 
Y1068F-EGFR, but not WT-EGFR in MEFs induced colony formation in soft agar in the presence of 2 
ng/ml EGF. C) Expression of both WT-HER2 and Y1139F-HER2 in MEFs induced robust colony 
formation in soft agar. D) Pictures of colonies, one at 10 and another at 5 objectives for each 
group, showing effect of EGFR silencing on colony formation by the Skbr-3 HER2-positive breast 
cells. Scale bar represents 500 μm. E) Bar graph showing differences in colony size formed by the 
control and EGFR-shRNA cells after 10 days of incubation in soft agar. F) Bar graph showing colony 
number as determined by counting 10 random fields under 4 objective and then averaging; data 
shown is mean  S.D. (standard deviation) of three independent experiments. G) Pictures of mice 
bearing xenograft tumors initiated by subcutaneous injection of ~106 BT20-HER2 cells expressing 
control or EGFR-specific shRNA. Note the differences in size and shape where the shRNA are 
smaller and relatively rounded while the controls are larger and irregular. H) Pictures of isolated 
tumors also show differences in size and shape. I) Bar graph showing differences in tumor weight 
between the control and the shRNA cells; data shown is average weight of the three tumors in each 
group  S.D. (standard deviation). 
 
Figure S1: Expression of HER2 in the MCF-10A (A) and BT20 (B) cell lines did not lead to increased 
total protein tyrosine phosphorylation. In fact, HER2 expression led to reduced tyrosine 
phosphorylation as at the level of EGFR and HER2 which suggests reduced receptor 
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autophosphorylation.. Note that EGFR in the HER2 cells is resistant to EGF-induced degradation, 
and HER2 itself was unaffected by EGF stimulation in both the MCF-10A and BT20 derived cells.  
 
Figure S2: A) Expression WT-EGFR in MEF cells and addition of 2 ng/ml EGF in the growth medium 
did not lead to any appreciable morphological changes, while expression of Y1068F-EGFR under 
same conditions resulted in morphological changes reminiscent of cell transformation. Note that 
the Y1068F-EGFR cells form foci-like cellular mass, suggesting loss of contact-induced growth 
inhibition. B) Expression of both WT-HER2 and Y1139F-HER2 led to transformation of MEF cells as 
evidenced by refractive appearance and formation of foci-like cellular mass. The foci-like structures 
are suggestive of absence of contact-induced growth inhibition.  
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Figure 3. Analysis of EGFR and HER2 co-precipitation with c-Cbl 
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The Src homology 2-containing protein tyrosine phosphatase (SHP2) is very well known for its 
positive role in cell growth and survival signaling induced by receptor tyrosine kinases (RTKs), 
including the epidermal growth factor family of RTKs. Furthermore, SHP2 is known to promote 
cell migration and invasiveness, key steps in cancer metastasis, in a variety of cell types, 
including breast cancer cells. To date, however, the mechanism by which this phosphatase 
regulates cell movement has not been fully elucidated. In the current report, a new role for 
SHP2 in controlling cell migration has been suggested. We show that SHP2 mediates 
lamellipodia persistence and cell polarity to promote directional cell migration in the MDA-
MB-231 and the MDA-MB-468 basal-like and triple-negative breast cancer cell lines. We 
further show that SHP2 modulates the activity of focal adhesion kinase (FAK) by 
dephosphorylating pTyr397, the autophosphorylation site that primes FAK function. Because 
hyperactivation of FAK is known to weaken nascent focal complexes and hence negatively 
regulate their maturation to focal adhesions, we propose that one of the mechanisms by which 
SHP2 promotes lamellipodia persistence is by downregulating FAK activity through 
dephosphorylation of pTyr397. The finding that inhibition of FAK activity partially restores 
epidermal growth factor-induced cell migration under conditions of SHP2 inhibition supports 
our proposition SHP2 promotes growth-factor-induced cell movement by acting, at least in 
part, on FAK. FAK inhibition did not rescue migration defects in SHP2-silenced cells under non-





The Src homology 2-containing phosphotyrosylphosphatase 2 (SHP2) is a cytosolic enzyme 
that catalyzes the hydrolysis of phosphate from tyrosine residues(139,140). As its name 
indicates, SHP2 contains two tandemSH2 domains in the N-terminal region and a phosphatase 
domain in the C-terminal region. In addition, SHP2 contains sites of tyrosine phosphorylation 
in the C-terminal tail region (140).  Structural studies have shown that the N-terminal SH2 
domain interacts with the catalytic site, resulting in autoinhibition by obstructing access to 
substrates.  Engagement of this domain with phosphotyrosine results in conformational 
changes that relieve the active site (39).  Therefore, factors that can upregulate cellular 
phosphotyrosine such as exposure of cells to receptor tyrosine kinase (RTK) ligands (141), 
overexpression or activating mutations of receptor tyrosine kinases, expression of the CagA 
protein in H. pylori infection (142), activation of integrins during matrix adhesion (143), and 
cytokine stimulation (144) can lead activation of SHP2.  In addition, mutations within the 
inhibitory SH2 domains of SHP2 can abolish autoinhibition, leading to constitutive activation 
(70,145). In fact, such mutations do occur in human diseases and are demonstrated to be the 
causes for disorders such as Noonan syndrome and associated cardiac disorders and 
hematopoietic malignancies (146). 
SHP2 typically acts as a positive mediator in a variety of signaling pathways (147). For 
example, SHP2 mediates EGF-induced signals to the Ras-extracellular signal-regulated kinases 
1 and 2 (ERK1/2) and the PI3K (phosphatidylinositol-3) – Akt (protein kinase B) pathways by 
counteracting RasGAP (Ras GTPase activating protein), an inducer of Ras inactivation. It does 
so, at least in part, by dephosphorylating RasGAP-docking sites on membrane proteins such as 
the epidermal growth factor receptor (EGFR) (49) and the human EGFR2 (HER2 also known as 
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ErbB2) (25) thereby blocking recruitment the plasma membrane where functional Ras resides. 
In addition, SHP2 has been shown to promote RTK signaling by inactivating Sprouty proteins 
which are responsible for receptor downregulation (148), and to enhance Src activation by 
dephosphorylating PAG (phosphoprotein associated with glycosphingolipid-enriched 
microdomains) which is known to act as a docking site for Csk, an inhibitor of Src (149). This 
positive effect on signaling has been shown to promote cell transformation and tumorigenesis. 
For instance, SHP2 is essential for cell transformation induced by the constitutively active 
fibroblast growth factor receptor 3 (150),the oncogenic form of Src (v-Src) (151) and the 
HER2oncogene (25). Recently, SHP2 was shown to be important for xenograft tumor growth of 
breast cancer cells (152).The discovery that the SHP2 protein is overexpressed in breast 
cancer (28) further strengthened the notion that SHP2 plays critical roles in breast cancer and 
possibly in other cancers where tyrosine kinase signaling is the driving force.   
SHP2 has been shown to regulate cell migration in a variety of ways (63,153,154), a 
process that is known to promote cancer metastasis. For instance, SHP2 modulates focal 
adhesion dynamics (64,67), RhoA activity (155), and integrin signaling (63) which are all 
implicated in regulating cell migration. To date, however, the mechanism by which SHP2 
controls cell migration has not been fully understood.  Because SHP2 overexpression is 
strongly correlated to breast cancer metastasis (28), we sought to explore its role in cell 
migration in basal-like and triple-negative breast cancer (BTBC) cell lines, which are known to 
be highly invasive. In this report we show that SHP2 promotes cell migration by mediating 
directional cell polarization and lamellipodia persistence, which are key steps in this process. 
We further show that SHP2 regulates the activity of focal adhesion kinase (FAK) through 
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dephosphorylating pTyr397 (pY397), the autophosphorylation site that controls the kinase 
activity, to promote cell migration.  
4.3) Materials and Methods 
4.3.1) Cells and reagents  
Cells used in this study included wild type and focal adhesion kinase-null murine embryonic 
fibroblasts (MEFs) kindly provided by Dr. Steven Frisch (West Virginia University) and the 
MDA-MB-231 and the MDA-MB-468 BTBC cell lines purchased from ATCC. All cells were 
grown in Dulbecco's modified eagle medium supplemented with 10% fetal bovine serum at 37 
oC and 5% carbon dioxide. The polyclonal (cat.# SC-280) and the monoclonal (cat.# SC-7384) 
anti-SHP2 antibodies were from Santa Cruz, the FLAG-tag (cat. #F1504) and anti-β-actin 
antibodies (cat #A5441) were from Sigma-Aldrich, focal adhesion kinase (cat #F15020), 
phospho-Y397-FAK (cat #F25420) and anti-GM130 (cat. #610823) were from BD biosciences, 
anti-cortactin antibody (clone 4F11) was a kind gift from Dr. Scott Weed (West Virginia 
University), and anti-paxillin antibody (cat #05-417) was from Upstate Biotechnology. The 
FAK inhibitor (PF-573228) was purchased from Pfizer.  
4.3.2) Silencing SHP2 expression with shRNA 
Double-stranded deoxyoligonucleotides that code for short hairpin ribonucleotides that target 
SHP2 mRNA were custom- synthesized (Integrated DNA Technology) and ligated into the 
BamHI and EcoRI sites of a lentivirus backbone termed pLSL-Puro (a gift from Dr. Peter 
Chumskoy, Cleveland Clinic Foundation) in a manner similar to Ivanov, et al (156). We used 
the targeting sequences 5’-GTATTACATGGAACATCAC-3’ and 5’-GAAGAATCCTATGGTGGAA-3’ 
which were previously shown to be SHP2 specific (157). The shRNA construct and supporting 
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plasmids (pCMV-SVV-G and sPax2) were transected into 293T packaging cells using the 
turbofect transfection reagent (Fermentas). After 48 h, supernatants containing viral particles 
were collected, filtered using 0.22 μm syringe filter and used for infecting the BTBC cell lines. 
Polybrene at concentration of 3 µg/ml was added to enhance the infection efficiency. After 48 
hours, cells were treated with 4 µg/ml puromycin to remove non-infected ones. A short 
hairpin against luciferase was used as a control in these studies.  
4.3.3) Site-directed mutagenesis, subcloning and expression 
FAK cDNA in a pCMV-SPORT6 vector, purchased from ATCC, was used as the template for site-
directed mutagenesis using a Stratagene kit (cat.# 600250). The Y397F sense and anti-sense 
primers were 5'-TCAGAAACAGATTTTGCTGAGAT and 5'-ATCTATAATCTCAGCAAAATCATCTG, 
and the Y407F sense and anti-sense primers were 5'-GATTATAGATGAAGAAGATACTTTCA and 
5'-CTGGTTGAGGGCATGGTGAAAGTATC. The wild-type and the mutant FAK cDNA were then 
subcloned into the viral vector reported previously (115) at XhoI and NotI sites using the 
forward primer containing a SalI site (5'-TTTGTCGACCGCCACCATCGCAGCT-3’), and a reverse 
primer containing a NotI site (5'-TTTTGCGGCCGCCTATTTATCATCATCAT-3’).Subcloning FLAG-
tagged SHP2 into a retroviral vector and expression in target cells was described previously 
(25). Retroviral particle production, infection of target cells, selection and production of 
population of cells stably expressing FAK proteins were also performed as described for SHP2 
proteins previously (25). Populations of cells stably expressing SHP2 or FAK proteins were 
used for the various experiments described in the relevant sections. 
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4.3.4) Preparation of cell lysates, immunoprecipitation and immunostaining 
Cells were lysed in a buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1% Triton-X-100, 10% glycerol, and 50 mM NaF supplemented with 10 µg/ml each of 
aprotinin, leupeptin, and PMSF for protease inhibition, and 10mM sodium orthovanadate for 
inhibition of phosphatases. For immunoprecipitation, the lysates were cleared by 
centrifugation at 12,000 rotations per minute, incubated overnight with a primary antibody, 
and then precipitated using protein G sepharose beads. The beads were washed 3 times with 
cell lysis buffer and denatured by boiling with Laemmli sample buffer. The same denaturation 
procedure was used for analyzing total cell lysates. Denatured proteins were separated on 8% 
or 10% polyacrylamide gel by electrophoresis, immobilized onto a nitrocellulose membrane, 
blocked with 3% bovine serum albumin in Tris-buffered saline containing 1% Tween-20 
(TBST), and stained with a primary antibody overnight at 4oC. Next, membranes were washed 
3 times with TBST and then incubated with a horseradish peroxidase-conjugated secondary 
antibody in 5% milk. The immunostains were visualized by the enhanced chemiluminescence 
method (Pierce Inc.).  
4.3.5) Monolayer wound-healing assay 
The MDA-MB-231 and the MDA-MB-468 cells (expressing control shRNA or SHP2 shRNA) 
were grown to confluency in 6 cm dishes. A scratch was made using a P-200 pipette tip, and 
cell migration was monitored and pictures collected under an Olympus IX-71 microscope 
equipped with a CCD camera. For EGF-stimulated migration, cells nearing confluence were 
serum starved overnight, wounds made in the same manner as above, re-fed with serum-free 
media, and then treated with 100 ng/ml EGF for 2 hours or left untreated. The Olympus 
Microsuite software was used to estimate the cell-free area of the wounds.  The change in the 
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wound width was estimated by dividing the area with the constant length of the images taken 
at 4x objective similar to that reported by Tao, et al (158). 
4.3.6) Immunofluorescence 
Cells were seeded on fibronectin-coated coverslips and grown for the indicated time points 
described in the respective figure legends. They were then washed twice with room-
temperature PBS, fixed in 3.5% paraformaldehyde in PBS for 20 minutes, permeabilized with 
0.6% Triton X-100 in PBS for 30 minutes, incubated in 3% bovine serum albumin (BSA) in PBS 
for 1 hour at room temperature, and incubated with primary antibodies overnight at 4 oC. 
Alexafluor 488-conjugated rabbit and Alexafluor 568-conjugated mouse secondary antibodies 
were used to detect antigens. Images were captured using an Olympus IX71 microscope with 
attached CCD camera and Microsuite Basic Edition software. 
4.3.7) Assay for golgi orientation 
Cells were seeded on fibronectin-coated coverslips and grown to confluency after which 
monolayer wounds were made by scratching with P-200 pipette tip. The cells were allowed to 
close the wound for approximately 6 hours and were then processed for immunofluorescence 
staining with anti-GM-130 antibody (golgi marker) as described above. 10 fields of fluorescent 
pictures per slide were obtained at 10x magnification and were analyzed for golgi orientation 
as described previously (159). At least 1000 cells per slide were counted in this way. 
4.3.8) Live-cell imaging and kymographic analysis 
Cells expressing either control shRNA or SHP2 shRNA were transiently transfected with 3 µg of 
mCherry-actin (Clontech) using the FuGene 6 transfection reagent (Roche), incubated 
overnight, and transferred onto fibronectin-coated Bioptechs DeltaT dishes. Once adhered, the 
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cells were starved overnight, stimulated with 100 ng/ml EGF, and imaged using the Nikon 
TE2000S inverted microscope with attached Photometric Cool snap HQ CCD camera. Images 
were collected every 5 seconds for 20 minutes using the TRITC filter to visualize actin. The 
movies taken were saved as TIFF image sequences for import into ImageJ. Kymographic 
analysis was performed as described previously (160). Briefly, the multiple kymograph plugins 
were used to draw plots of protrusion dynamics. Persistence was the time from the initiation 
of protrusion until the initiation of retraction.  
4.3.9) Substrate-trapping, affinity precipitation and far western analysis 
Substrate trapping with the double-mutant (D425A and C459S) SHP2 (DM-SHP2) and affinity 
precipitation with the GST fusion of the PTP domain of DM-SHP2 (DM-PTP) were performed as 
described previously (25,49). For Far Western analysis, FLAG-tagged FAK constructs (wild 
type, Y397F, and Y407F) were immunoprecipitated after plating cells on fibronectin to induce 
phosphorylation, and this enriched FAK was separated on SDS-PAGE before transfer onto 
nitrocellulose membranes. The membranes were then incubated overnight with 100 ng/ml of 
DM-PTP in TBST plus 5% BSA overnight at 4 oC, probed with anti-GST antibody for 2 hours at 
room temperature, and detected as described in the immunostaining section.  
4.3.10) In vitro phosphatase assay 
FAK-null MEFs expressing WT FLAG-FAK were seeded on fibronectin to activate FAK.  The 
cells were lysed using iodoacetic acid to permanently inhibit endogenous phosphatases.  10 
mM DTT was then added to quench the remaining iodoacetic acid. Equal amounts of protein 
(100 µg as assessed by the BCA assay) was added to a phosphatase reaction buffer at pH7.2 
(25 mM HEPES, 150 mM NaCl, and 1 mM EDTA) along with 1 µg of purified, recombinant SHP2 
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lacking the N-terminal SH2 domain.  The reaction was allowed to proceed for the indicated 
time periods at 37ºC before terminating with Laemmli sample buffer and boiling.  The assay 
was run in parallel with no added PTP to control for possible residual endogenous PTP activity.   
4.3.11) Statistical analyses 
GraphPad Prism was used to make the graphs as well as to determine confidence intervals and 
run statistical tests.  To gauge significance of data, unpaired, two-tailed t-tests were run with 
95% confidence intervals. 
4.4) Results 
4.4.1) SHP2 is required for basal as well as EGF-stimulated BTBC cell motility 
Past work has shown SHP2 to be a critical factor in fibroblast migration through transwell 
assays (153). In addition, the importance of SHP2 in breast cancer cell migration has been 
suggested based on wound healing assays (161). Here, we wished to explore the impact of 
SHP2 inhibition on the rate of cell motility. To this end, we inhibited SHP2 protein levels in two 
prototypical BTBC cell lines, the MDA-MB231 and the MDA-MB468, using two shRNA that 
were previously demonstrated to be specific for silencing SHP2 expression (157). As shown in 
Fig.1A, both shRNA constructs silenced SHP2 protein expression by greater than 90%. We then 
subjected these cells to a wound-healing assay under normal growing conditions. Inhibition of 
SHP2 with both shRNA-1 (data not shown) and shRNA-2 (Fig.1B) resulted in a clear loss of 
wound healing ability. Since we noted similar defects in wound healing using both shRNA-1 
and 2, we opted to continue further experiments with shRNA-2 due to its slightly better 
inhibition of protein expression, especially in MDA-MB468 cells.  
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To obtain further insights on the impact of SHP2 inhibition, the rate of wound closure 
was estimated by calculating changes in wound dimension over 8 hours following scratching. 
The 8 hour time point was chosen because it represents a time when cells were still linearly 
migrating before contacting each other from opposite directions, especially in the controls. 
Multiple pictures of the monolayer wound were taken at the 0 and the 8 hour time points, and 
the cell-free area of each photograph was measured in microns using the Olympus Microsuite 
Basic Edition software. The average area was divided by 2190 microns, the image length of 
each photograph taken at 4x objective, to arrive at average wound width. Changes in wound 
width between the 0 and the 8 hour time points were used for comparison of the control and 
the shRNA cells. While the control MDA-MB231 and MDA-MB468 cells had reduced the wound 
width by an average of 325 and 461 microns in 8 hours, respectively, the corresponding 
shRNA cells had reduced by approximately 220 and 306 microns, respectively. In other words, 
while the control cells of MDA-MB231 and MDA-MB468 cells were closing the wound at a rate 
of 40 and 57 microns per hour, respectively, the corresponding shRNA cells were closing at a 
rate of 27 and 38 microns per hour, respectively (Table 1 and 2). Therefore, depletion of SHP2 
retards wound healing.  
SHP2 is well-known for its positive role in growth factor-related signaling, especially 
that of epidermal growth factor (EGF) (49). EGF is known to stimulate cell motility in both the 
MDA-MB-231 (162) and the MDA-MB-468 (163) cells, and EGF receptor is known to be 
overexpressed in a large number of triple-negative breast cancers.  Therefore, we wished to 
determine whether SHP2 is required for EGF-stimulated cell migration. We performed similar 
measurements to estimate wound closure rate over 2 hours in the presence of EGF (100 
ng/mL). This time point was chosen based on our previous studies where  we demonstrated 
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that EGF-induced signaling drops significantly within 2 hours due to degradation of the 
receptor (164). EGF stimulation induced a modest motility response in the controls, resulting 
in a 20-30% increase in wound healing rate, but this response was not observed in the shRNA 
cells (Fig.1D and E). These results suggest that SHP2 can exert control over EGF-induced cell 
movement, which is unsurprising given its known role as a promoter of growth factor receptor 
signaling. 
4.4.2) SHP2 promotes proper cell directionality during wound healing 
Previous studies have shown that inhibition of SHP2 induces marked changes in cell 
morphology (165), indicating that SHP2 may play a role in cell polarization.  To test this 
hypothesis, we subjected BTBC cells to wound-healing on fibronectin-coated glass coverslips 
and stained the golgi body, since this organelle becomes oriented toward the wound in 
response to cell polarization (159).  In both the MDA-MB231 and the MDA-MB468 cell lines, 
inhibition of SHP2 expression resulted in a significant loss of the population of cells with golgi 
oriented toward the wound (Fig.2A and B).  Control cells tended to orient toward the wound 
approximately 60% of the time, while SHP2-depleted cells oriented about 40% of the time 
(Fig.2C), indicating that SHP2 is indeed critical for the establishment of cell polarity during 
migration in BTBC cells. 
4.4.3) SHP2 is recruited to the leading edge of BTBC cells 
The impaired polarization and migration of SHP2-depleted cells suggested that SHP2 may 
function at the cell membrane to promote motility, which is not surprising sinceSHP2 is 
primarily known to act at the plasma membrane (166). Using immunofluorescence, we 
analyzed for SHP2 localization under steady-state conditions (Fig.3).We co-stained 
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endogenous SHP2 along with cortactin, a marker of the leading edge, in the MDA-MB231 
(Fig.3A) and the MDA-MB468 (Fig.3B) cells.SHP2 was found prominently colocalized with 
cortactin at the leading edges of the control cells, and, as expected, this signal was not readily 
detectable in SHP2-depleted cells, in the meantime serving as a specificity control for the anti-
SHP2 antibody. These results strongly indicate that SHP2 is recruited to the leading edge of 
cells. 
4.4.4) SHP2 depletion alters EGF-stimulated membrane protrusions in BTBC cells 
The presence of SHP2 at the cell periphery along with the effects of SHP2 depletion on EGF-
stimulated motility led us to hypothesize that SHP2activity may exert control over membrane 
protrusions, specifically the dynamics of lamellipodia. We transfected the MDA-MB231 and the 
MDA-MB468 cells with mCherry-actin (Clontech) to visualize actin-rich lamellipodia in real-
time. These cells were seeded on fibronectin-coated DeltaT (Bioptechs) dishes prior to 
stimulation with EGF, and kymographs of individual membrane protrusions were generated 
using ImageJ (Fig.4A).  In general, SHP2 depletion resulted in protrusions showing more sharp 
peaks, suggesting a defect in persistence. Lamellipodia persistence was further quantified as 
described by Bryce, et al (167) to better characterize the result of SHP2 depletion. Persistence 
was measured as the time from initiation of the protrusion to initiation of retraction. While 
persistence in the control MDA-MB231 cells was about 60 seconds, it was only about 30 
seconds in the corresponding shRNA cells, an approximately 50% drop caused by SHP2 
inhibition (Fig.4B). The drop in lamellipodia persistence in the MDA-MB468 cells caused by 
SHP2 silencing was even more drastic. While the control cells showed an approximately 220 
seconds persistence, the corresponding shRNA cells exhibited an average of 70 seconds, an 
approximately 70% drop in persistence (Fig.4C). Importantly, in both MDA-MB231 and MDA-
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MB468 cells, depletion of SHP2 resulted in lamellipodial persistence induced by EGF that was 
indistinguishable from non-stimulated cells, mirroring the defects in EGF response shown in 
Fig. 1D and 1E.  These data suggest that SHP2 is especially important for control of protrusion 
persistence. 
4.4.5) pY397 in FAK is a target for SHP2 PTPase activity   
To obtain insights on the mechanistic of SHP2 regulation of cell migration, substrate-trapping 
studies were conducted in mouse embryonic fibroblasts (MEFs) in which SHP2 was previously 
shown to regulate the activity of focal adhesion proteins (165).FLAG-tagged wild type SHP2 
(WT-SHP2), substrate-trapping SHP2, also referred to as DM-SHP2 (DM for D425A and C459S 
double mutant that cannot catalyze hydrolysis but retains substrate binding capability) or 
vector alone was expressed in MEFs as described in the materials and methods and in previous 
reports (25). Cells were seeded on fibronectin-coated plates to stimulate tyrosine 
phosphorylation of adhesion proteins, and lysates prepared from them were subjected to 
immunoprecipitation with anti-FLAG antibody. Immunostaining with anti-pTyr antibody 
showed coprecipitation of an approximately 120 kDa protein with the DM-SHP2, but not with 
vector or the WT-SHP2 (Fig.5A, top), suggesting that the co-precipitation was due to substrate 
trapping as reported previously. Based on previous suggestion that FAK might be an SHP2 
substrate (64,67) the same preparations were probed with anti-FAK antibody. Indeed, the 120 
kDa tyrosine-phosphorylated protein trapped by the DM-SHP2 was FAK (Fig.5A, middle). 
Reprobing with anti-FLAG antibody showed that both WT-SHP2 and DM-SHP2 proteins were 
effectively precipitated although the WT-SHP2 protein level was higher than the DM-SHP2 
(Fig.5A, bottom). These results confirm previous studies which suggested that FAK is an SHP2 
substrate. 
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Previously identified SHP2 substrates possess acidic amino acids N-terminal to the 
target phosphotyrosine (25,49). We thus suspected that Tyr397 andTyr407 (Y397 and Y407), 
which have such residues in the immediate N-terminal region, might be substrates. To test this 
hypothesis, FLAG-tagged wild type or mutant FAK (Y397F and Y407F) were expressed in FAK-
null (FAK-/-) MEFs, and lysates prepared from these cells were subjected to affinity 
precipitation with GST-DM-PTP.  As shown in Fig.5B, precipitation of FAK required pY397, 
since its mutation abrogated binding. On the other hand, mutation of Y407 did not affect 
binding, suggesting that it was not a target for SHP2. Reprobing with anti-GST antibody 
confirmed that the amount of GST-DM-PTP was comparable in all lanes. Analysis of input total 
cell lysates showed that the three FAK proteins were expressed comparably (Fig.5C). In order 
to eliminate the possibility of indirect interaction, we performed Far Western analysis 
(Fig.5D). In this assay, FLAG-tagged FAK proteins described above were immunoprecipitated 
from MEFs seeded on fibronectin, resolved by polyacrylamide gel electrophoresis, transferred 
onto a nitrocellulose membrane, blocked with BSA and probed with the GST-DM-PTP as 
described in the materials and methods. Anti-GST was then used to detect SHP2 binding. The 
results closely mimicked the affinity precipitation showing that pY397 was required for the 
binging of DM-PTP. Reprobing with anti-FLAG antibody showed that the amount of the 
different FAK proteins recovered from the immunoprecipitation reactions was comparable. 
These binding results suggest that SHP2 directly regulates FAK by acting on pY397. 
In order to assess the ability of wild type SHP2 to directly dephosphorylate FAK in vitro, 
we subjected MEF cell lysates expressing FLAG-tagged FAK to incubation with purified GST-
WT-PTP lacking the regulatory SH2 domains. Immunostaining with anti-pY397 and anti-pY576 
showed that SHP2 preferentially dephosphorylated pY397, but not pY576 (Fig.5E). Reprobing 
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with anti-FLAG antibody showed the presence of comparable amount of FAK protein in all 
lanes. These results clearly show that pY397 in FAK is a substrate for SHP2 which in turn 
suggest that SHP2 regulates FAK activity by acting directly on the autophosphorylation site, 
pY397.Our results partially disagree with a previous report that suggested that both pY397 
and pY576 are SHP2 substrates (168). The observed discrepancies might have been caused by 
differences in experimental approaches. In the current work, purified PTP was used as an 
enzyme as opposed to immunoprecipitated SHP2, a step that cannot exclude coprecipitation of 
other PTPs. The use of purified PTP also allows accurate control of enzyme concentration. 
Furthermore, we did employ iodoacetate treatment of total cell lysates containing FAK to 
irreversibly inhibit endogenous PTPs before PTPase reaction, a step not taken by the other 
report (168).   
We next wished to confirm in the BTBC cell lines whether FAK pY397 could be 
mediated by SHP2.  To this end, we seeded cells on fibronectin coverslips and gave them 
sufficient time to attach and spread.  Immunofluorescence against pY397 showed a differential 
localization when SHP2 was inhibited.  Focal adhesions containing pY397 appeared larger and 
more numerous than in controls, suggesting a role for SHP2 in the regulation of these 
complexes and the level of pY397 during adhesion and spreading (Figs 5F and 5G). 
4.4.6) SHP2 promotes FAK inactivation to promote EGF-stimulated wound healing 
The results described in Fig.1D and E, demonstrated that SHP2 was required for EGF-induced 
wound healing, while those presented in Fig. 5 showed that SHP2 modulates FAK tyrosine 
phosphorylation by acting on pY397, the autophosphorylation site known to regulate FAK 
activity. It was thus reasoned that SHP2 mediates EGF-stimulated cell migration by 
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inactivating FAK and the phenotype induced by silencing SHP2 is a result of FAK 
hyperphosphorylation. We first examined the role of SHP2 in the regulation of pY397 levels 
during EGF stimulation.  Confluent monolayers of MDA-MB231 (Fig. 6A) and MDA-MB468 (Fig. 
6B) cells were serum-starved overnight before stimulation with EGF.  In the MDA-MB231 
control cells, EGF induced no significant change in the pY397 signal, while the MDA-MB468 
cells exhibited a modest increase of approximately 20%.  In both cell lines, depletion of SHP2 
caused no significant change to pY397 under serum-starved conditions, but stimulation by EGF 
in both cases induced a marked activation of FAK.  In MDA-MB231 shRNA cells, EGF stimulated 
resulted in an approximately 50% increase of pY397, whereas in the MDA-MB468 cells the 
increase was nearly 80% (Fig. 6A and 6B, lower panels).  These results clearly indicate SHP2 is 
essential for preventing FAK hyperactivation under EGF stimulation.   
SHP2 appeared to be playing an antagonistic role in FAK activation during EGF 
stimulation.  Therefore, PF-573228, a FAK inhibitor (169), was used to inhibit kinase activity. 
This compound is known to completely inhibit focal adhesion kinase at 10μM concentration 
and above, but we hypothesized that if the role of SHP2 was to fine-tune the dynamic 
regulation of FAK phosphorylation, then adding a lesser amount of the inhibitor should rescue 
some of the defects we observed in SHP2-depleted cells.  To this end, we applied 10n M PF-
573228 to BTBC cells in the EGF-induced assays.  
First, we noted that treatment with PF-573228 had no effect on the pY397 levels in 
control MDA-MB231 cells.  In MDA-MB468 cells, we noted a slight decrease equating to 
approximately 20%.  Despite the low to nonexistent inhibition of pY397 at these 
concentrations, we found that FAK inhibition was able to completely prevent the 
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hyperactivation induced by EGF treatment in the shRNA cells.  Thus, we assessed EGF-
stimulated wound healing experiments in a manner similar to Figs. 1D and 1E.  We observed 
that a concentration of 10 nM FAK inhibitor had no significant effect on the rate of wound 
healing in control and shRNA BTBC cell lines under basal growing conditions; however, when 
the FAK inhibitor was applied to shRNA cells followed by EGF stimulation, we noted an 
increase in wound healing rate of approximately 20-30% in the shRNA cells (Fig.7A and B), a 
difference similar to the EGF-induced increase seen in control cells (compare with Fig.1D and 
E).   
Since aberrant FAK activation has been linked to decreased nascent adhesion strength 
(64,67), we reasoned that the FAK inhibitor could rescue the defects in EGF-stimulated 
lamellipodia persistence observed upon SHP2 depletion.  The 10 nM PF-573228 FAK inhibitor 
was able to reverse the loss of persistence as evidenced by the occurrence of long-lasting 
protrusions (Fig.7C and D) similar to those seen in the control cells (Fig.4).  We also wished to 
determine whether FAK inhibition could rescue the defects observed in cell polarity.  We 
repeated the experiments presented in Fig. 2 in the presence and absence of 10 nM PF-573228 
(Fig. 7E).  The inhibitor showed no alterations in the percentage of cells that were properly 
oriented during wound healing.  Taken together, these results indicated that SHP2 was 
involved in attenuating FAK phosphorylation during EGF treatment. This fine-tuning of FAK 
activation resulted in increased wound healing after treatment with EGF, presumably through 




Cell migration is one of the mechanisms utilized by a tumor cell to locally invade and 
eventually metastasize to distant tissues and organs to initiate secondary tumors, which is 
often the cause of death from cancer. SHP2 has been known to influence cell migration for 
more than a decade (63,153,165), and much of the study into this phenomenon has focused on 
its putative regulation of either focal adhesion dynamics (64,67) or RhoA activity 
(155,170,171). In this report, we have shown for the first time that SHP2 regulates 
lamellipodia dynamics and golgi orientation during motility.  
In order to assess the significance of SHP2 in BTBC, the highly metastatic form of breast 
cancer, we investigated whether or not it plays a role in cell migration. In line with this goal, 
we have demonstrated that SHP2 is required for BTBC cell migration (Fig. 1). These findings 
agree with our own and other previous reports where a positive role for SHP2 in cell migration 
was demonstrated (25,67,150), although those reports utilized different cell contexts. 
Furthermore, the current data provide additional insight by showing that SHP2 promotes cell 
migration by enhancing cell polarization, the pathfinding step in cell migration.  
SHP2 is a well-known effector of EGFR signaling, a receptor tyrosine kinase 
overexpressed in approximately 70% of BTBC (172,173), including the cell lines used in this 
study, the MDA-MB231 and the MDA-MB468. It was thus logical to test if SHP2 is required for 
EGF-induced cell migration under these contexts. We have found that both cells were 
unresponsive to EGF-induced wound healing when SHP2 was depleted (Fig. 1D), suggesting 
that SHP2 plays essential roles in EGFR-induced migration of BTBC cells in addition to its 
regulation of basal cell migration (Fig.1B). This regulation of EGF-dependent migration by 
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SHP2 is not trivial since EGFR is regarded as a contributing factor for the aggressive 
manifestations of BTBC (174,175). Our findings imply that SHP2 may prove to be an effective 
therapeutic target in triple-negative breast cancers. 
Data presented in Fig.2 demonstrate that cells in which SHP2 is depleted show defects 
in their ability to orient themselves toward the space created by the monolayer wounding. 
These results clearly demonstrate that one of the mechanisms by which SHP2 promotes cells 
migration is by mediating proper cell polarization. Recruitment of SHP2 to the leading edge of 
a migrating cell (Fig. 3) supports this possibility and suggests a direct role for SHP2 in cellular 
path finding. This is not surprising given the evidence that SHP2’s cellular function is enhanced 
by its interaction with tyrosine-phosphorylated proteins at the plasma membrane (176). 
SHP2 appears to be important in EGF-induced lamellipodia persistence (Fig. 4), an 
event that allows effective lamellipodia extension and forward cellular movement. 
Lamellipodia persistence requires temporal strengthening of nascent adhesions or maturation 
of nascent adhesion complexes to focal adhesions. The recruitment of SHP2 to the leading edge 
of a migrating cell (Fig.3) suggests its regulation of lamellipodia persistence by acting on 
adhesion proteins like paxillin and focal adhesion kinase (FAK) which were previously 
suggested to be SHP2 substrates (168,177). In support of this possibility, a previous work in 
SHP2-null fibroblasts showed instability of focal adhesion proteins at ECM-cell contacts which 
could be rescued either with dominant negative FAK or with reintroduction of wildtype SHP2 
(67). Under these conditions, FAK has been shown to be hyper-activated, suggesting that it 
counteracts maturation of nascent complexes to focal adhesions. Indeed, hyper-activated FAK 
has been shown to sequester paxillin away from nascent adhesion, leading to weakening of 
86 
these adhesions and presumably inhibiting lamellipodia persistence (168). These findings lend 
support to the possibility that SHP2 regulation of FAK tyrosine phosphorylation plays a key 
role in lamellipodia persistence.  
By employing intracellular substrate-trapping studies and in vitro phosphatase assays, 
we have demonstrated that FAK is an SHP2 substrate (Fig.5), which is in agreement with 
previous suggestions (168). We have further shown that the preferred site of SHP2 action in 
FAK is pY397 as opposed to the closely-related pY576 and pY407. This preference for pY397 
suggests that SHP2 not only regulates FAK autophosphorylation, but also subsequent 
recruitment of Src, preventing further activation. Therefore, our findings are consistent with 
SHP2 promoting cell migration by enhancing lamellipodia persistence through down 
regulation of FAK activity. Cell migration is a dynamic process that involves adhesion and 
deadhesion to the ECM. At this stage, it is not known whether or not SHP2 is also involved in 
the deadhesion process, and if yes, what substrates it acts on to promote deadhesion. It will be 
interesting to address these questions in future studies. 
The observation that mild FAK inhibition is able to rescue the EGF responsiveness in 
SHP2-depleted BTBC cells (Figs. 6 and 7) provides further support to the idea that SHP2 acts to 
down regulate FAK to promote nascent adhesion strengthening. Strengthening of focal 
adhesions by antagonizing FAK signaling was also noted in the initial characterization of the 
inhibitor (169). In that study, concentrations of the drug that inhibited the majority of FAK in 
cells were shown to strongly inhibit cell motility in part due to the lost focal adhesion 
dynamics. Taken together, excessive FAK activation will result in increased focal adhesion 
dynamics and low traction, leading to poor motility, while a low level of FAK activity promotes 
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the anchorage of cells through the aberrant formation of non-dissociable focal adhesions. 
Therefore, fine tuning FAK activity seems to be essential for EGF-induced lamellipodia 
persistence and strengthening of focal complexes to focal adhesions. Our data suggest that 
SHP2 attenuates FAK activity to promote EGF-induced cell migration. Interestingly, FAK 
inhibition did not rescue the wound healing defects under normal growing conditions 
observed upon SHP2 inhibition, suggesting the existence of other FAK-independent 
mechanisms for control of cell migration by SHP2. This observation warrants further 
investigation in future studies. 
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4.7) Figure Legends 
Figure 1. 
A, silencing SHP2 protein expression in the MDA-MB231 and the MDA-MB468 cells using 2 
specific shRNA constructs designated as shRNA-1 and shRNA-2. Anti-β-actin immunostaining 
was used as a loading control. Control and shRNA cells derived from the MDA-MB231 (B) and 
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the MDA-MB468 (C) were grown to confluence followed by wounding with a P200 pipette tip. 
Images of wounds were taken at 0- and 24-hour time points. Rate of wound closure per hour in 
8 hours in the MDA-MB231 (D) and the MDA-MB468 (E) was estimated by dividing the overall 
change in wound space similar to that described in Table 1. Data presented are mean ± SEM. 
***, P < 0.001 and **, P < 0.01. Representative images of control and shRNA cells derived from 
the MDA-MB231 (F) and MDA-MB468 (G) stained with 4′,6-diamidino-2-phenylindole (DAPI) 
and GM130 after 6 hours of wound healing are shown. Arrowheads represent cells that were 
considered as oriented to the wound. H, Golgi orientation was calculated as a percentage of 
cells at the wound edge with stained Golgi facing the wound space. Ten fields of cells were 
gathered per independent experiment, totaling more than 500 cells for each cell line. Data are 
presented as mean ± SEM. 
Figure 2. 
SHP2 localizes to the leading edge of BTBC cells. The control and the shRNA cells derived from 
the MDA-MB231 (A) and the MDA-MB468 (B) lines were seeded on fibronectin-coated 
coverslips and were allowed to attach overnight. Cells were then fixed, permeablized, and 
stained with anti-cortactin and anti-SHP2 antibodies. Exposure times to acquire images of 
SHP2 staining were held constant between control and shRNA slides. Arrows indicate leading 
edges of cells. 
Figure 3. 
Bar graphs showing the impact of SHP2 silencing on EGF-induced wound healing over a period 
of 2 hours in the MDA-MB231 (A) and the MDA-MB468 (B) cells. SHP2 depletion alters EGF-
stimulated membrane protrusions in BTBC cells. C, kymographs of movies collected from live-
cell imaging experiments for both the MDA-MB231 and MDA-MB468 cells are shown. 
89 
Kymographs were used to calculate the persistence of the lamellipodia in the MDA-MB231 (D) 
and the MDA-MB468 (E) cells in a manner described by Kelley and colleagues (160). Data 
presented are mean ± SEM of protrusion persistence time in seconds collected from at least 10 
cells per cell line. ns: nonsignificant. *, P < 0.05. 
Figure 4. 
SHP2 regulates FAK activity in BTBC cells. A, substrate-trapping studies in MEFs expressing 
vector alone, FLAG-WT-SHP2, or FLAG-DM-SHP2. Cells were seeded on fibronectin for 30 
minutes, and lysates prepared from these cells were subjected to anti-FLAG 
immunoprecipitation followed by immunostaining analysis with anti-pTyr, anti-FAK, and anti-
FLAG (for SHP2) antibodies. B, in vitro affinity precipitation with GST-DM-PTP of cell lysates 
prepared from FAK-null MEFs expressing vector alone or FLAG-tagged FAK proteins. The 
precipitates were analyzed by immunostaining with ant-FLAG antibody for FAK proteins and 
with anti-GST for GST-DM-PTP. C, input total cell lysates used for affinity precipitation were 
stained with anti-FLAG, anti-pY397, and anti-β-actin antibodies. D, far Western blot analysis 
with GST-DM-PTP to show that the presence of pY397 is needed for binding. E, in vitro 
phosphatase assay using WT FAK as a substrate and purified WT SHP2 as an enzyme. 
Immunostaining results for pY397, pY576, and FAK (FLAG-FAK) are shown. NP, no PTP. 
Figure 5. 
Analysis of impact of SHP2 silencing on the pY397-FAK levels. The control and the shRNA cells 
derived from the MDA-MB231 (A) and MDA-MB468 (B) were grown to about 90% confluence, 
serum-starved for approximately 4 hours, and then left unstimulated or stimulated with 100 
ng/mL EGF for 20 minutes. Lysates prepared from these cells were analyzed by 
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immunostaining with anti-pY397 antibody. Bar graphs show band density measurements of 
the anti-pY397 staining from 3 independent experiments. The MDA-MB231 (C) and the MDA-
MB468 (D) cells grown on coverslips were stimulated with the same concentration of EGF and 
then analyzed by immunofluorescence microscopy after staining with anti-pY397 antibody. 
The 4′,6-diamidino-2-phenylindole (DAPI) staining also was conducted to show the nucleus. 
Figure 6. 
Effect of FAK inhibition on EGF-induced wound healing, lamellipodia persistence, and Golgi 
orientation. SHP2-depleted MDA-MB231 (A) and MDA-MB468 (B) cells were grown to 
confluence before scratching with a pipette tip. Cells were then fed with serum-free medium 
and left untreated or treated with 10 ng/mL FAK inhibitor (PF) and 100 ng/mL EGF. Rate of 
wound healing was assessed in the same manner as in Fig. 3A and B. Live-cell imaging was 
used to assess EGF-induced lamellipodia persistence in the presence and absence of PF (10 
nmol/L) in theMDA-MB231 (C) and the MDA-MB468 (D) cells. Data presented are mean ± SEM 
of protrusion persistence time in seconds collected from at least 10 cells per cell line. E, effect 
of the FAK inhibitor on Golgi orientation. Analysis of pY397-FAK levels in the MDA-MB231 (F) 




























5) Substrate discrimination by the Src homology 2-containing protein 
tyrosine phosphatase SHP2 predicted by molecular docking 
5.1) Abstract 
The tyrosine phosphatase SHP2 is a positive regulator of mitogenic and cell survival signaling. 
In the signaling of receptor tyrosine kinases, especially EGFR and HER2, SHP2 is known to act 
on binding sites for RasGAP. However, it is not clear exactly how SHP2 recognizes these 
sequences selectively. In this report, a substrate-based peptide is shown to be a selective 
inhibitor for SHP2 over its homologue SHP1.  The proto-oncogene HER2 was expressed in 
MCF-10A cells, and a mutation upstream of the phosphotyrosine 1023 abolished association 
with the SHP2 active site. This dissociation of the SHP2-HER2 interaction correlated with 
impaired EGF-induced signaling and transformation normally induced by HER2. 
Computational docking of the substrate-derived peptide identified SHP2 arginine 362 and 
lysine 364 as key mediators of binding.  These data suggest key substrate-protein interactions 
that allow for selective binding. 
5.2) Introduction 
The Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a cytosolic PTP that 
mediates many important signaling networks (178).  It contains two tandemly-arranged SH2 
domains that generate intramolecular autoinhibition of the catalytic active site.  Binding to 
phosphotyrosine induces a conformational change that relieves this inhibition (39).  When 
active, SHP2 functions to promote signaling related to proliferation (179), survival (180,181), 
and motility (153).  This positive functionality of SHP2 is critical for promotion of different 
forms of cancer (52). In cells, SHP2 is required for maintenance of the transformed phenotype 
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of fibroblasts expressing an oncogene (115). It is also required to promote the mesenchymal 
state and anchorage-independent survival in breast cancer cell lines (161).  Thus, targeting 
SHP2 with small molecules appears to be an attractive means of combating cancer, but 
development of these inhibitors has proved challenging.   
To date, numerous studies have been published characterizing inhibitors based on high-
throughput chemical and in silico drug screens (182-186).  A few common challenges have 
appeared through this work.  First, moieties used to mimic phosphotyrosine tend to be 
charged, rendering the compound impermeable to the cell membrane.  Selectivity of these 
compounds is another significant issue.  The active sites of PTPs are well-conserved in 
sequence and overall charge distribution (187).  Thus, many drugs that target SHP2 tend to 
target other PTPs, especially its homolog SHP1.  This is an especially-important issue to 
overcome since SHP1 is a negative mediator of signaling (188).  The most selective inhibitors 
for SHP2 have been shown to achieve approximately 20-fold selectivity for SHP2 over SHP1 
(184), which leaves significant room for improvement.  
SHP2 is known to selectively bind substrates in vitro (189).  This observation suggests that the 
issue of drug selectivity can be surmounted.  Unfortunately, the intermolecular determinants 
of selective substrate binding to SHP2 have not been elucidated.  A study exploring the peptide 
sequence best-recognized by SHP2 has been published (190).  The specific molecular 
interactions required for selective binding remain to be elucidated, however.  Numerous 
crystal structures of unbound (39) and small molecule inhibitor-bound SHP2 (186) have been 
published, but to date no study has been undertaken to elucidate the molecular determinants 
of a substrate binding to SHP2.  To this end we have performed docking experiments along 
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with biochemical validation to test how a substrate-based inhibitory peptide is able to 
selectively inhibit SHP2 over SHP1.  The results presented herein suggest the presence of key 
electrostatic and steric interactions that allow the peptide to bind SHP2 but not SHP1 and help 
pave the way toward selective SHP2 inhibitor design. 
5.3) Materials and Methods 
5.3.1) Cells, cell culture, and reagents 
The immortalized mammary epithelial cell line MCF-10A were purchased from American 
Tissue Culture Collection (ATCC). These cells were cultured in Dulbecco's modified Eagle's 
medium supplemented with 10 μg/ml recombinant human insulin, 20 ng/ml EGF (PeproTech), 
0.5 μg/ml hydrocortisone, 100 ng/ml cholera toxin (Sigma), and 5% horse serum. Other 
reagents used included the DiFMUP kit (Invitrogen) and glutathione-sepharose beads (GE 
Healthcare); peptides corresponding to the SHP2 target site of EGFR (DADEpYL) were 
synthesized and purified to greater than or equal to 95% by NeoPeptide, Inc.   
The anti-HER2 antibody was from Sigma. Anti-phospho-ERK 1/2 and phospho-Akt 
were from Cell Signaling, Inc. The anti-RasGAP antibody was from BD Biosciences. 
 
5.3.2) Purification of recombinant GST fusion proteins 
The method used for expressing and purifying the GST fusion of the PTP domain of SHP1 and 
SHP2 has been described previously (25). To summarize, E. coli expressing the plasmid pGEX 
with either SHP2 or SHP1 were grown overnight in 100 mL luria bertani (LB) broth. Then the 
culture was diluted 1:5 with LB and was stimulated with 1 mM IPTG for approximately 3 h. 
The bacteria were harvested by centrifugation before lysis in a buffer containing 20 mM 
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HEPES, 120 mM NaCl, 10% glycerol, 0.5% NP-40, and 2 mM EDTA. Sonication was used to 
assist the lysis, and then the lysate was incubated for 30 minutes with Triton X-100 before 
being cleared by centrifugation. The supernatant was applied to a slurry of glutathione 
sepharose beads overnight at 4°C. The beads were washed with lysis buffer three times, and 
the protein was eluted using reduced glutathione (10 mM) in tris buffer. The eluted product 
was collected and stored in -80oC with 10mM dithiothreitol. The Bradford assay (Biorad, City, 
State) was used to quantify the product. 
5.3.3) In vitro phosphatase activity assay 
Purified SHP2 or SHP1 lacking the regulatory SH2 domains was diluted to a concentration of 5 
nM with phosphatase reaction buffer (50mM HEPES, 100 mM NaCl, and 2 mM EDTA, pH=7.2).  
Difluoromethylumbelliferryl phosphate was used as an artificial substrate at a concentration of 
20 uM or 35 uM, corresponding to the Km for SHP2 and SHP1, respectively.  Varying 
concentrations of peptide (sequence DADEpYL corresponding to the substrate phospho-Y992 
of EGFR) were used to assess which concentration resulted in 50% inhibition.  Graphpad Prism 




5.3.4) Site-directed mutagenesis, subcloning, and expression of HER2 
HER2 cDNA in a pCMV-SPORT6 vector, purchased from ATCC, was used as the template for 
site-directed mutagenesis using a Stratagene kit (600250). The sense and the antisense 
primers for the E1021A substitution were 5’-
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GGACCTGGTGGATGCTGCGGAGTATCTGGTACCCCAGCAG-3’ and 5’-
CTGCTGGGGTACCAGATACTCCGCAGCATCCACCAGGTCC-3’. Both the wildtype and mutant 
cDNAs were then ligated into the REBNA/IRES/GFP viral vector reported previously at XhoI 
and NotI sites using the forward primer containing a SalI site (5’-
TTTGTCGACCGCCACCATCGCAGCT-3’) and a reverse primer containing a NotI site (5’-
TTTTGCGGCCGCCTATTTATCATCATCAT-3’) (25). Retroviruses were generated, and MCF-10A 
cells were infected to stably express the wildtype and HER2 mutant as described previously 
using blasticidine selection (1 μg/mL) (25). 
5.3.5) Preparation of cell lysates, immunoprecipitation, and immunostaining 
Cells were lysed in a buffer containing 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1% Triton-X-100, 10% glycerol, and 50 mM NaF supplemented with 10 μg/mL each of 
aprotinin, leupeptin, and phenylmethylsulfonylfluoride (PMSF) for inhibition of proteases, and 
10 mM sodium orthovanadate for inhibition of phosphatases. For immunoprecipitation, the 
lysates were cleared by centrifugation at 12,000 rpm, incubated overnight with a primary 
antibody, and then precipitated using protein G sepharose beads. The beads were washed 3 
times with cell lysis buffer and denatured by boiling with Laemmli sample buffer. The same 
denaturation procedure was used for analyzing total cell lysates. Denatured proteins were 
separated on 8% or 10% PAGE, immobilized onto a nitrocellulose membrane, blocked with 3% 
bovine serum albumin (BSA) in tris-buffered saline containing 1% Tween-20 (TBST), and 
stained with a primary antibody overnight at 4°C. Next, membranes were washed three times 
with TBST, incubated with horseradish peroxidase–conjugated secondary antibodies in 5% 
milk, washed three times with TBST, and visualized by the chemiluminescence method (Pierce 
Inc.). 
102 
5.3.6) Affinity precipitation 
The GST fusion of the PTP domain of doubly-mutated SHP2 (D425A and C459S, DM-SHP2) was 
used to affinity precipitate the wildtype and mutant HER2 as described previously (25). 
Briefly, cells at 80% confluence were incubated with 1 mM vanadate for 30 minutes before 
stimulating with EGF (100 ng/mL) for 10 minutes. Lysates were then incubated with purified 
GST-DM-SHP2 overnight at +4°C, and the resulting SHP2-substrate complexes were captured 
by incubating the mixture with glutathione sepharose beads for two hours at +4°C. The beads 
were then washed four times with lysis buffer before adding laemmli sample buffer and 
boiling. The denatured samples were then subjected to separation by SDS-PAGE and analysis 
by immunostaining. 
5.3.7) Anchorage-independent growth assay 
The soft agar assay was performed as described previously (84).  Briefly, 6 cm cell culture 
plates were coated with 0.5% agar in growth medium.  Approximately 1x105 cells were 
suspended in growth medium that was mixed with melted agar to a final concentration of 0.5% 
and were then poured onto the agar bed. After four weeks of incubation a minimum of 10 
fields at a 4x objective per plate were analyzed. Phase contrast pictures were taken using an 
Olympus IX71 microscope equipped with Olympus DP30BW digital camera, and colony size 
was estimated as a circular area using the measurement tools in Microsuite Basic Edition. 
Error bars represent the standard error of mean (SEM) of replicates. 
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5.3.8) Molecular docking 
was built in InsightII (Accelrys, Inc.) and saved as a pdb.  The docking pre-processing and data 
analysis were performed in Autodock Tools (191) and the grid and docking calculations were 
carried out by Autogrid4 and Autodock4 (192). Nonpolar hydrogens were removed from the 
peptide, and Kollman charges were added.  The relaxed enzyme pdb was then loaded, and an 
80x80x80 grid box with 0.375 angstrom grid spacing was placed around the point defined by 
the sulfur of the catalytic cysteine offset in the x direction by 16 angstroms.  Electrostatic maps 
for the ligand were calculated based on this grid, and then the genetic algorithm was applied to 
search for the best predicted binding structure of the peptide.  In each case a minimum of 2000 
runs were attempted.  Default parameters were used for the genetic algorithm with a few 
exceptions.  First, population size was increased to 400, and the number of energy evaluations 
was set at a high number to allow for the maximum number of generations, which was set at 
27000.  Autodock Tools was then used to identify the best predicted binding pose, and pictures 
and hydrogen bonding information were gathered. 
 
5.4) Results 
5.4.1) A substrate-derived peptide is a selective SHP2 inhibitor 
Previous reports showing discrimination by SHP2 of specific phosphotyrosine sites within the 
same protein (i.e., EGFR (49), HER2 (25), and FAK (168)) suggest that selectivity for substrates 
can be mediated by elements of the sequence surrounding the phosphotyrosine, as has been 
examined using library methods (193). Interestingly, when the primary sequences of the 
substrate and non-substrate phosphotyrosines were aligned, the presence of acidic amino 
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acids seemed to be the most common trend. This was especially noted for the -2 position, 
which is the only residue where the acidic amino acid is fully conserved and exclusive to 
substrates (Figure 1A).   
These observations led us to speculate that a phosphopeptide derived from the 
substrate sequence may act as a competitor to phosphatase activity. Since the endogenous 
substrate is thought to be selective for SHP2 as opposed to SHP1 (194,195), we hypothesized 
that the competition using this molecule would be similarly selective. A hexapeptide was 
synthesized to include the four amino acids N-terminal to the phosphotyrosine, since this 
region contained the highest amount of conserved acidic amino acids. The GST fusion of the 
PTP domains of SHP2 and SHP1 were purified as described in the materials and methods and 
used for in vitro phosphatase assays (196). The enzymatic activity of SHP2 and SHP1 toward 
the artificial substrate difluoromethylumbelliferryl phosphate (DiFMUP) was determined in 
the presence of different peptide concentrations. We determined the inhibitory constant, Ki, 
for the peptide against both enzymes, resulting in more competition for SHP2 compared with 
SHP1 (approximately 11.97 µM SHP2 vs 630.0 µM for SHP1) (Figure 1B).  These data support 
the hypothesis that a substrate-derived inhibitor of SHP2 does not readily inhibit SHP1, and 
selectivity for this inhibitor is based on the amino acids surrounding the phosphotyrosine. 
Since the acidic amino acid located at the -2 position in the substrate sequence was 
well-conserved and exclusive to substrate phosphotyrosine sequences (Figure 1A), a modified 
peptide was synthesized substituting the -2 position aspartate for alanine, removing the 
associated negative charge. This substitution effectively eliminated the inhibitory ability of the 
peptide when subjected to phosphatase assays against SHP2 (Ki = 856.8 µM, Figure 1B). These 
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results suggest that the conserved -2 position amino acid of the substrate is especially 
important for binding to SHP2. 
5.4.2) Mutation of HER2 abolishes interaction with SHP2 
Intracellular association of SHP2 with its substrates has been well established using the 
substrate-trapping, phosphatase-dead SHP2 mutant (DM-SHP2) (25,49,197). Since we 
observed that mutation in the substrate-derived peptide sequence was able to abrogate 
inhibition of the enzyme, we wanted to assess whether similar mutations in a full-length 
substrate could prevent its association with SHP2.  
Using site-directed mutagenesis, we introduced an aspartate-to-alanine substitution in 
the HER2 protein at position 1021, corresponding to the -2 position aspartate in the substrate-
derived peptide. Using a retroviral vector, the mutant or wildtype HER2 was expressed in the 
immortalized non-transformed breast epithelial cell line MCF-10A. Next, the cells were grown 
to near confluence before overnight starvation followed by vanadate treatment and EGF 
stimulation to enhance phosphorylation of HER2. Lysates were incubated overnight with a GST 
fusion of the DM-SHP2 PTP domain, and the resulting complexes were captured using 
glutathione sepharose beads. Wildtype HER2 was able to bind SHP2 in this context, whereas 
the Y1023F mutant HER2 was unable to form a complex with SHP2, as described previously 
(25). However, the D1021A mutant HER2 was unable to form a complex with SHP2 (Figure 
2A). This suggested either the D1021A mutant of HER2 was poorly phosphorylated due to 
altered recognition by a kinase domain, or the mutation abolished the binding capacity for 
SHP2. 
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Antibodies selective for phosphorylated Y1023 have yet to be developed, so direct 
testing of the phosphorylation status of this residue would prove challenging. It has been 
demonstrated, however, that phosphotyrosine 1023 acts as a major docking site for the SH2 
domain of p120 RasGAP (25), and if the phosphorylation status is intact, binding to RasGAP 
should be preserved. To this end, we immunoprecipitated RasGAP out of EGF-stimulated MCF-
10A cells expressing the HER2 proteins and probed for HER2 (Figure 2B). Both the wildtype 
and D1021A HER2 immunoprecipitated with RasGAP, while the Y1023F mutant did not to a 
significant extent. This suggests that the phosphorylation of D1021A HER2 at Y1023 was 
unaffected by the amino acid substitution, leading to the conclusion that the defective 
association with SHP2 is due to the removal of the acidic amino acid N-terminal to the 
phosphotyrosine. 
5.4.3) Disruption of HER2-SHP2 interaction reduces transformation by HER2 
It has been suggested that wildtype SHP2 promotes mitogenic signaling through HER2 by 
dephosphorylating tyrosine 1023 and preventing the association of RasGAP (25). We sought to 
determine the consequence of disrupting the SHP2-HER2 interaction while leaving the HER2-
RasGAP interaction in place. To test this, we assessed EGF-induced signaling in cells expressing 
wildtype and D1021A HER2. Overexpression of wildtype HER2 resulted in prolonged 
Ras/MAPK and Akt signaling compared with control cells (25) (Figure 3A). However, when 
D1021A HER2 is overexpressed instead, the signal was still prolonged compared with controls, 
but it was not as robust as in cells overexpressing the wildtype HER2.  
If the MAPK and Akt signaling cascades downstream of the HER2-SHP2 interaction 
were disrupted by mutation of HER2, then it should be expected that transformation by HER2 
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would be affected, as well. HER2 has been previously shown to promote transformation of 
MCF-10A cells as assessed by the soft agar assay, a measure of anchorage-independent growth 
(25). Therefore, we determined the effect of overexpressing mutant HER2 on formation of 
colonies in soft agar. As expected, wildtype HER2 formed significantly larger colonies 
compared with controls. However, when the D1021A mutant was overexpressed, the colonies 
were nearly 50% smaller on average compared with WT HER2-overexpressing cells (Figure 
3B). These colonies were significantly larger than control, suggesting that the mutant HER2 
maintained partial transformative capability. These observations in soft agar corresponded 
with those seen in the EGF-induced signaling cascades, where D1021A attenuated but did not 
eliminate the advantage conferred by overexpressing wildtype HER2 (Figure 3A). It should be 
noted that the MCF-10A cells are grown in cell media specifically supplemented with EGF, and 
this media was changed once every two days. Overall, these results support the hypothesis that 
SHP2 promotes HER2 signaling by dephosphorylating pY1023 following EGF stimulation, 
preventing recruitment of RasGAP and subsequent attenuation of the MAPK signaling cascade. 
5.4.4) Molecular modeling predicts binding determinants of SHP2 and substrate 
The results described so far suggested that binding of substrate by SHP2 is supported by 
negatively-charged amino acids upstream of the phosphotyrosine. Indeed, the region 
surrounding the active site of SHP2 is highly-positively charged, moreso in general than its 
homologue SHP1 (198). In order to assess how the substrate-based peptide binds to SHP2 
selectively, we performed molecular docking studies using Autodock to predict binding of the 
peptide used in Figure 1 to the SHP1 and SHP2 active sites. The DADEpYL peptide was docked 
into the SHP2 active site of 2SHP.pdb (with SH2 domains stripped from the structure) using 
the genetic algorithm. At least 2000 runs were performed, and the most favorable 
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conformation was selected to predict the interaction (Figure 4). We ensured that the 
phosphotyrosine was situated inside the active site near the nucleophilic cysteine, an essential 
step of the PTP catalytic mechanism (78). In these data, actual amino acid numbers in the SHP2 
protein were used to refer to residues in the active site, while the position in reference to the 
pY was used to assign numbers to the residues in the peptide. Accordingly, residues N-terminal 
to the pY were assigned with negative numbers while those positioned C-terminal to the pY 
were given positive numbers.  
Electrostatic interactions were computed in Autodock tools to estimate binding 
energies. Strong ionic contacts were found between arginine (R) and lysine (K) residues of the 
SHP2 active site and the acidic residues of the substrate peptide (Table 1), with the most 
prominent being between K364 and the aspartate residue at the -2 position (-6.737 kcal/mol). 
Other strong predicted interactions included two contacts between R362 and the aspartate in 
the -4 position of the peptide (-2.827 and -3.653 kcal/mol). The -2 aspartate also interacted 
with K366 (-0.113 kcal/mol). Finally, the -1 glutamate residue of the peptide was predicted to 
hydrogen bond with Y279 of SHP2 (-2.903 kcal/mol). The total intermolecular interaction 
energy was found to be -14.3 kcal/mol with -8.50 kcal/mol originating from Van der Waals 
interactions and hydrogen bonds and -5.80 kcal/mol provided by electrostatic interactions. We 
also calculated the predicted Ki of the peptide, which was found to be 9.72 µM.  
To obtain further insight into the active site differences, the same peptide was docked 
into the SHP1 active site (Figure 5). Out of more than 2000 runs, the best structure predicted a 
Ki of 641 µM, a rather dramatic loss of predicted inhibition compared to SHP2 (9.72 µM). 
Analysis of the structure revealed many electrostatic contacts between the peptide and the 
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active site (Table 2). R358, which is analogous to K364 of SHP2, was predicted to form an ionic 
bond with the -2 position aspartate of the peptide (-4.518 kcal/mol). Another electrostatic 
interaction was found between H420 and the -1 glutamate of the peptide (-3.67 kcal/mol).  
The geometry of the predicted interactions was influenced by steric clashes.  The orientation 
and size of R358 appeared to create a pocket that required deformation of the peptide and 
atom contacts with the active site, resulting in a lowered overall binding energy. 
5.5) Discussion 
This work demonstrates for the first time that a PTP substrate-based inhibitor can act as a 
selective antagonist of SHP2 activity compared to SHP1, a closely-related PTP family member. 
Here we have shown that critical interactions occur between active site basic residues and 
acidic residues of the peptide substrate.   
Our initial observation that the substrate-derived peptide acted as a selective antagonist of 
SHP2 activity led to the idea that negatively-charged sidechains must play a critical role in 
SHP2 recognition of substrates, an idea that has been suggested by numerous studies 
(185,186,190,199). We have demonstrated for the first time, however, the critical importance 
of acidic amino acids to binding, since removal of even one of these residues (the -2 position 
aspartate) abolishes competition for substrate in the in vitro experiments (Figure 1B). We took 
this observation one step further, expressing the substitution in a cellular context with a bona 
fide SHP2 substrate, HER2. This mutant HER2 failed to associate with SHP2 via affinity 
purification (Figure 2A), but its ability to coprecipitate with RasGAP indicates that the Y1023 
residue is still phosphorylated despite the mutation (Figure 2B). This suggests that recognition 
of negatively-charged sidechains is important for SHP2 substrate determination in vivo as well 
as in vitro.  
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Interestingly, the lost association correlated with a loss of signaling longevity in response 
to EGF (Figure 3A), presumably due to preserved binding of the inhibitor RasGAP. This is in 
agreement with the model for SHP2 mediation of HER2 signaling that was proposed previously 
(25). This signaling defect carried over to a defect in transformative capacity of HER2 in an 
anchorage-independent growth assay, further indicating a survival promoting role of the 
SHP2-HER2 interaction (Figure 3B). 
Molecular docking was used as a tool to predict how selective binding is achieved. 
Specifically, electrostatic interactions of substrate acidic sidechain-containing amino acids 
with active site arginine 362 as well as lysine 364 (substituted to lysine and arginine in SHP1, 
respectively) were found to strongly mediate the binding.  In addition, the difference in size of 
these amino acids resulted in unfavorable steric interactions when docked to SHP1 but not 
SHP2.    We found that interactions with K364 of SHP2 conferred a significant amount of 
electrostatic stability, especially to the -2 position aspartate residue of the DADEpYL peptide 
inhibitor.   We experimentally confirmed that this -2 position acidic amino acid was important 
for binding in vitro, in support of our computational docking results.  The importance of the 
substrate’s negatively-charged sidechains binding to the region containing R362 and K364 
suggested that selectivity for SHP2 is derived primarily from distinct characteristics of this 
region.  Interestingly, the first known SHP2 inhibitor, NSC-87877, was shown to be non-
selective between SHP2 and SHP1, and docking in that study revealed that the positively-
charged region of the active site was not engaged by this compound at all, which may help to 
explain its lack of selectivity for SHP2 over SHP1 (183).   
The differences in the predicted energies of polar contacts revealed special importance of 
sidechain interactions to the binding of acidic residue-containing peptides to SHP2, but not 
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necessarily SHP1. Side chain interactions between the peptide’s acidic residues and the active 
site resulted in a total energetic stabilization  twice as  large for SHP2 (-16.238 kcal/mol) as for 
SHP1 (-8.756 kcal/mol).  This may explain why SHP2 is able to bind and selectively 
dephosphorylate EGFR pY992, while SHP1 does not.  It also supports the idea that SHP1 and 
SHP2 have divergent active site selectivity determinants, and this selectivity is not due to 
trafficking by their unique SH2 domains (200). 
In conclusion, we have presented data elucidating specific substrate-SHP2 intermolecular 
interactions that are present during binding of a substrate-derived phosphopeptide inhibitor 
of SHP2.  Interactions with a positively-charged region of the active site that are conserved in 
sequence, but not structure between SHP2 and SHP1, are found to be present and appear to be 
critical for inhibition as determined by in vitro assays.  This substrate-derived peptide shows 
substantial selectivity for SHP2 over SHP1, an improvement over currently-published 
inhibitors.  While we do not expect this peptide to be an acceptable therapeutic agent in itself, 
we expect that the knowledge of selectivity determination will be useful in the development of 
improved small molecule inhibitors.  
 
5.6) Figure Legends 
Figure 1. a) The major phosphotyrosine sites in EGFR and HER2 were overlaid for comparison; 
common features to SHP2 substrate sequences were analyzed, and a substrate-derived peptide 
was synthesized. b) Activity of the substrate-derived peptide was assessed in competition with 
the fluorogenic difluoromethylumbelliferryl phosphate in increasing concentrations to arrive 
at an IC50 as described in Materials and Methods. The modified substrate, with the -2 position 
aspartate substituted, showed no activity toward SHP2. 
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Figure 2. a) Whole cell extracts of MCF-10A cells expressing either vector control, WT-HER2,  
1023F-HER2, or 1021A-HER2 following EGF stimulation (25). 
b) MCF-10A cells expressing wildtype or mutant HER2 were stimulated with EGF for 10 
minutes, and lysates were subjected to immunoprecipitation with RasGAP to determine 
phosphorylation status of Y1023.  
c) Whole-cell extracts of MCF-10A cells described in “a” were incubated overnight in the 
presence of GST-DM-SHP2 and glutathione-sepharose beads. Captured complexes were 
washed four times and then were immunoblotted for HER2. 
Figure 3. a) MCF-10A cells overexpressing wildtype or mutant HER2 were stimulated with EGF 
(100 ng/mL) over the given time points. Lysates were subjected to SDS-PAGE and 
immunoblotting. 
b) MCF-10A cells were subjected to an anchorage-independent growth assay as described 
previously (84). Briefly, 1x10^5 cells were suspended in a 0.5% agar and were allowed to 
grow, refreshing media every two days. Colony size was estimated as a circular area based on 
10 different fields of colonies per replicate. Data are presented as mean±SEM. ***, p<0.001 
Figure 4. a) EGFR Y992-derived peptide was docked into the SHP2 active site using Autodock4, 
and the binding mode is presented with SHP2 residues represented using the molecular 
surface model. 
b) Interactions between the peptide and the SHP2 active sites.  Peptide residues are labeled 
based on their sequence position relative to the phosphotyrosine.  Polar contacts are indicated 
by green dots. 
113 
 
Figure 5. a) EGFR Y992-derived peptide was docked into the SHP1 active site using Autodock4, 
and the binding mode is presented with SHP1 residues represented using the molecular 
surface model. 
b) Interactions between the peptide and the SHP1 active sites.  Peptide residues are labeled 
based on their sequence position relative to the phosphotyrosine.  Polar contacts are indicated 





Figure 1. Derivation of a substrate-derived peptide that selectively inhibits SHP2 
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Figure 2. Mutation of HER2 abolishes interaction with SHP2 
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Figure 3. Mutation of HER2 results in attenuated response to EGF stimulation and inhibits transformation 
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Figure 5. Predicted binding mode of substrate-derived peptide to the SHP1 active site 
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Table 1. Predicted electrostatic interactions between the substrate-derived peptide and the SHP2 active site  
Peptide to SHP2 Energy* 
-1 Glu to Y279 -2.903 
-2 Asp toK364 -6.737 
-2 Asp to K366 -0.113 
-4 Asp to R362 -2.827 
-4 Asp to R362 -3.653 
*Energy given in kcal/mol   
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Table 2. Predicted electrostatic interactions between the substrate-derived peptide and the SHP1 active site 
Peptide to SHP1 Energy* 
-1 Glu to H420 -3.67 
-1 Glu to K356 -0.301 
-2 Asp to R358 -4.518 
-2 Asp to R358 -0.26 
-4 Asp to K356 -0.007 





The overall goal of the work presented in this report is to add to the growing body of evidence 
supporting SHP2 as a therapeutic target in breast cancer. At this time, more than half of all 
oncology drug development focuses on dissecting and targeting tyrosine kinases (30). Many of 
the seminal discoveries in targeted therapy have been made with respect to tyrosine kinases, 
including the development of imatinib (targeting Bcr/Abl) and trastuzumab (targeting HER2), 
among others. Unfortunately, these research efforts, while representing a paradigm shift in 
cancer therapy, have yet to achieve the ultimate goal: eradicating cancer. Therefore, the search 
continues for novel drug targets. 
Our study into protection of EGFR by HER2 illustrates an important trait of breast 
cancer, flexibility. Targeting of one pathway—in this case, HER2 signaling-- via upstream 
inhibition has been problematic since the introduction of trastuzumab. Up to half the patients 
with HER2-positive disease fail to respond to this therapy at all (201). A combined approach to 
breast cancer therapy is clearly needed. These combination therapies, however, have been 
slow to evolve. Many questions arise with this strategy. First, does combination therapy 
improve outcome? Several large studies have examined targeting receptor tyrosine kinases at 
multiple points. For example, combination lapatinib (a small molecule HER2 kinase inhibitor) 
plus trastuzumab led to an overall improved response to therapy when compared with either 
agent alone (202). Second, is combination therapy more toxic? Additive toxicity has been a 
significant challenge so far in combination therapy. Lapatinib plus trastuzumab leads to severe 
diarrhea and liver enzyme changes, but these effects were manageable in the trial (202). 
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Toxicity profile changes can become so severe, however, that the trial must be terminated, as 
was the case with combination bevacizumab (an antibody that scavenges vascular endothelial 
growth factor, VEGF) and sorafenib (a small molecule VEGFR kinase inhibitor) (203). In all, it is 
clear that multi-agent therapy creates new challenges. If these initiatives fail, scientists lose 
years of effort. 
 As of today, targeted breast cancer therapy focuses mainly on the upstream mediators 
of signaling. Many agents act either at the level of the extracellular domain or the kinase 
domain of receptor tyrosine kinases. While these drugs have improved the lives of many 
patients, disease relapse is a common outcome. One reason for this phenomenon is the ability 
of cancer cells to recruit redundant pathways to promote survival and growth. Indeed, the 
Cancer Genome Atlas project results illustrate just how complex breast cancers can become 
(22). Many tumors with HER2-positive or triple-negative phenotypes show activation of 
seemingly-unrelated receptor tyrosine kinases (i.e., fibroblast growth factor receptor). Thus, 
even with multiple agents, targeting the upstream mediators of signaling is challenging.  
 To date, cancer drug trials have not targeted downstream integrators of signaling. 
Previous work has demonstrated the importance of SHP2 in the proliferation and survival of 
cancer cells, helping to define SHP2 as a bona fide proto-oncogene (204). Increasing its activity 
can contribute to breast cancer tumorigenesis and progression (27,28,84). SHP2 promotes the 
activity of every known breast cancer-related receptor tyrosine kinase pathway, including 
EGFR and FGFR family members, to name a few. Transgenic mouse models and xenografts (27) 
have established key pre-clinical data showing that SHP2 is a critical mediator of breast 
tumorigenesis and maintenance.  
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Further support for targeting SHP2 comes from multiple studies analyzing breast 
cancer patient samples. SHP2 overexpression correlates with higher tumor grade and worse 
outcome (27,28,85). The first paper in this line demonstrated an association between SHP2-
positivity and lymph node metastasis, a feature of advancing carcinoma that often portends the 
development of incurable, metastatic cancer (28). 
Targeting of SHP2 has the added advantage of being impervious to many of the 
resistance mechanisms that challenge inhibition of receptor tyrosine kinases. For example, 
HER2-positive disease can overcome trastuzumab therapy via ectodomain shedding or 
through activation of growth factor pathways. Small molecule inhibitors of the HER2 kinase 
domain can be resisted through mutations that prevent binding of the small molecule while 
retaining ATP-binding capacity. An inhibitor targeting SHP2 would face neither of these 
challenges, since 1) it possesses no targeted domain it can shed to avoid binding an inhibitor 
and 2) any mutation that would abolish binding to a substrate-mimicking inhibitor would 
likely inhibit binding to endogenous substrates, as well, suppressing SHP2’s function. 
The other two studies presented in this paper address two differing aspects of SHP2 
biology and the hypothesis that SHP2 is a useful therapeutic target in breast cancer. From 
these studies, we can make two major conclusions: 1) SHP2 controls an important component 
of metastasis in breast cancer cells, and 2) Design of selective SHP2 inhibitors is possible. 
6.1) SHP2 controls one component of metastasis in breast cancer cells 
 
In line with the correlation between overexpressed SHP2 and metastasis, we have published 
results indicating the importance of SHP2 in wound healing of triple-negative breast cancer 
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cells. Wound healing is analogous to tumor cell movement along tracks of tissue or bone in 
vivo, a component of metastasis (205). SHP2 is an important regulator of adhesion and motility 
signaling (64), but a clear picture of the mechanisms for this control has remained elusive. We 
presented live-cell data demonstrating that SHP2 controls growth factor-stimulated 
lamellipodial dynamics. Specifically, inhibition of SHP2 hinders persistence of these structures, 
which may account for the some of the overall defect of these cells to move in response to EGF 
stimulation.  
 The formation and maturation of nascent adhesions following protrusion is one 
important constituent of lamellipodial persistence (206). SHP2 was previously shown to 
control adhesion strengthening of cells in other contexts (67). In agreement with von Wichert, 
et al., we found that inhibition of SHP2 upregulated FAK activation, which enhances focal 
adhesion dynamics and lower adhesion strengthening (67). In our study, the mechanism of 
persistence and a role for FAK activity downregulation were not clear from our data alone. 
However, other lines of evidence point to several mediators. One of these is α-actinin, an actin-
binding protein that becomes phosphorylated by FAK and stabilizes stress fibers. When SHP2 
is inhibited, the phosphorylation of α-actinin rises, as well, leading to aberrant stress fiber 
formation and enhanced cell contractility, weakening adhesions (67).  
A more speculative hypothesis of nascent adhesion control involves the phosphoprotein 
Nudel, which has never been experimentally established to function alongside SHP2. Despite 
this lack of evidence, Nudel possesses interesting functions that relate to our study. First, it is 
trafficked specifically to nascent adhesions, where it helps to promote their strength. It 
accomplishes this feat, at least in part, by binding paxillin, though the full mechanism is not 
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understood (207). When FAK is in its open conformation (e.g., following phosphorylation of 
Y397 and subsequent phosphorylation of the activation loop via recruitment of Src), it binds 
and sequesters paxillin, preventing binding of Nudel. In this context, SHP2, through 
dephosphorylation of FAK pY397, could prevent this sequestration, thus promoting nascent 
adhesion strength.  
 Regardless of the mechanism, SHP2 control of triple-negative breast cancer cell motility 
supports the hypothesis that this enzyme as a viable target in breast cancer. In particular, 
control of growth factor-related motility by SHP2 is useful in triple-negative cancer for two 
reasons. First, this subtype of cancer results in higher cancer-related mortality despite its 
relatively-low incidence (10). This is primarily due to the predisposition of triple-negative 
cancers to metastasize. The lack of hormone receptors and HER2 removes clinicians’ only 
approved targeted therapies, so options are more limited for these patients. Second, triple-
negative cancers often overexpress EGFR (172), so control by SHP2 presents an enticing focus 
for future therapy. 
6.2) Design of selective SHP2 inhibitors is possible 
 
Development of inhibitors against SHP2 has gained momentum in the last decade (208). The 
first compound developed to target SHP2 ran into the two major problems the field has 
encountered so far: cell permeability and selectivity (209). This compound, NSC-87877, was 
found using a high-throughput screen of the NCI diversity set. It demonstrated the highest 
potency against SHP2 of any compound to date, with an IC50 of approximately 300 nM. 
Unfortunately, activity against the homologue SHP1 was almost identical, demonstrating that 
NSC-87877 was not a selective compound. Inhibition of SHP1 in combination with SHP2 is an 
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undesirable effect of therapy, since SHP1 generally plays a negative role in signaling within its 
milieu, the hematopoietic system. Owing to the tumor suppressor function of SHP1 (210), co-
inhibition with SHP2 may lead to malignancy. In addition, NSC-87877 required concentrations 
as high as 50 μM to inhibit the MAPK pathway downstream of EGF stimulation, since the 
phosphomimetic moiety utilized (a sulfonate) was negatively charged at physiologic pH, 
rendering the compound cell impermeable.  
One of the compounds that has given the most insight and promise for targeting SHP2 is 
also one of the most recent. The salicylic acid-containing scaffolds yield effective SHP2 
inhibitors while maintaining drug-like properties (211). The major lead compound from this 
work, II-B08, exhibits somewhat selective inhibition of SHP2 over SHP1 and other 
phosphatases (approximately 3-fold selectivity). Interestingly, this publication presented the 
first real structural clues about the binding mode of small molecule inhibitors to SHP2. II-B08 
crystallized with the SHP2 active site and gave the first picture of inhibitor binding, with 
strong interactions being made to the phosphotyrosine binding pocket as well as surrounding 
amino acids. This crystal structure is novel due to the challenge of crystallizing any molecule 
with SHP2, substrate or inhibitor, to the extent that the quality of the structure presented with 
II-B08 is disputed (Dr. Nicholas Lawrence, personal communication).  
II-B08 has had the most success in moving through pre-clinical experiments. It has been 
used in two different animal-based models of malignancy, including mutant c-Kit-induced 
myeloproliferative disorders when combined in a regimen with a PI3K inhibitor (212). II-B08 
was also tested in a mouse model of non-small cell lung carcinoma (NSCLC), the most common 
form of lung cancer (213). Inhibition of SHP2 via a small molecule resulted in reduced EGF-
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stimulated MAPK and Akt induction; in addition, the growth of NSCLC cell xenografts was 
significantly suppressed in animals treated with II-B08.  The cells grafted into the animals 
harbored a genetic mutation in the EGFR gene, conferring the classic T790M substitution that 
renders the protein insensitive to small molecule inhibition by kinase inhibitors such as 
gefitinib. While promising, the rate of metastasis of the xenografts was not explored, and the 
relative lack of selectivity for II-B08 still leaves a potential issue: inhibition of SHP1 in the 
hematopoietic compartment and possible resultant malignancy. This question was not 
explored in the studies published so far, and the issue of drug selectivity remains. 
 Many insights regarding SHP2 selectivity have been inferred by SHP2-drug interactions 
(185,186,190,199); however, no lab has yet taken a substrate-based approach to deduce 
selective binding determinants. Our mutagenesis work represents the first demonstration of a 
mutated upstream recognition sequence in a substrate ablating binding of SHP2. The result 
was a HER2 molecule with intact RasGAP binding that was less able to promote signaling than 
wildtype. This HER2 mutant still promoted signaling and transformation, but it was to a lower 
extent compared with wildtype HER2. These results help to answer two questions that have 
lingered since our lab’s first exploration of HER2 and SHP2 in 2009 (25): 
1) Are upstream acidic amino acids important for recognition of substrates by SHP2? 
At the in vitro and cellular level, we were able to clearly confirm the importance of an acidic 
amino acids at the -2 position of a SHP2 substrate. This observation should not be taken to 
mean, however, that only the -2 position is key in decision making for SHP2. The modeling data 
suggested that removal of any of the three upstream negatively-charged sidechains would 
significantly impair binding, but these other positions-- the -1 and -4 positions of the DADEpYL 
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peptide-- were not explored heavily in the study. The reason was that the -2 position was the 
only acidic amino acid in all of the known EGFR/HER2 autophosphorylation sites that was 
present in only the Y992/Y1023 sequences. Other phosphotyrosines had acidic amino acids at 
the -1 and/or -4 positions, making a definitive conclusion of importance to binding more 
difficult.  
 The result of this study was the discovery of a model inhibitory compound with 
improved selectivity for SHP2 over SHP1 compared with previously-developed small molecule 
inhibitors. In our data, this selectivity was above 50-fold. If these observations can be 
translated into a peptidomimetic compound, then we hypothesize that selectivity of anti-SHP2 
molecules can be improved dramatically. 
2) Is RasGAP inhibition the major route of SHP2 enhancement of HER2 signaling? 
Our lab’s study of SHP2 regulation of HER2 signaling and transformation demonstrated several 
important findings (25). First, SHP2 recognized only the pY1023 site of the protein. Mutation 
of other candidate phosphotyrosines had little to no effect on co-precipitation with SHP2. 
Second, mutation of Y1023 to phenylalanine ablated the binding of both SHP2 and RasGAP, 
strongly promoting downstream signaling. This suggests a role for SHP2 as the inhibitor of the 
inhibitor in this context; however, SHP2 has been shown to control receptor tyrosine kinase 
signaling through other pathways, as well (78). In addition, total ablation of RasGAP binding to 
HER2 alone does not prove that inhibition of its recruitment by SHP2 is the major mechanism 
for promoting transformation. Introduction of a D1021A mutation appeared to have no effect 
on the recruitment of RasGAP. This was expected since the binding of SH2 domains is known to 
proceed primarily through sequences N-terminal to phosphotyrosines. The resulting inhibited 
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signaling and transformation are consistent with the hypothesis that the major role of SHP2 in 
promoting HER2-induced signaling is dephosphorylation of pY1023 and impaired recruitment 
of inhibitory factors such as RasGAP. 
 Discrimination of substrates by SHP2 has remained a mystery to the field since SHP2 
was discovered. Early studies using peptides to determine SHP2 selectivity gave some 
indication about residues that might be important for SHP2 to recognize and act upon a 
substrate, but these were not conclusive (214). A more systematic and comprehensive 
approach was later taken to determine selectivity using a peptide library and a novel bead 
assay (190). Unfortunately, this report was only able to arrive at a few conclusions. First, SHP2 
preferred acidic amino acids at any position N-terminal to the phosphotyrosine. Second, SHP2 
was highly unlikely to act on a substrate peptide with a lysine or an arginine residue. 
Interestingly, the -2 position was most strongly predicted to be an aspartate residue, as is the 
case with our model substrate-based peptide. While enticing, this report did not solve the 
unanswered questions regarding atomic interactions needed for SHP2 binding.  
 Ideally, determination of substrate-active site interactions would be determined by 
crystallography. However, no such structure has been determined. Thus, computational 
modeling was a valuable predictive tool to determine the binding mode of a substrate. The 
finding that electrostatic interactions with R362 and K364 of the SHP2 active site would create 
the most stable binding is a notion that has been forwarded by other modeling studies of small 
molecules (185,186,199). An interesting corresponding observation is the predicted binding 
mode of the original SHP2 inhibitor, NSC-87877 (209). When the researchers in this study 
docked the compound to the active site, the sulfonate interacted with the phosphotyrosine 
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binding pocket as expected, but the basic region containing arginine 362 and lysine 364 were 
neglected entirely in favor of a hydrophilic region across from it. I speculate that the lack of 
selectivity of this molecule may be related to this lack of interaction with the basic region, 
though this has yet to be tested. Another interesting observation was noted in the paper 
describing the most selective SHP2 inhibitor to date, PHPS1 (199). The only residue in the 
basic region this molecule was predicted to engage was the arginine 362. This was 
demonstrated to be important through mutation of R362, which ablated the inhibition by 
PHPS1. Combining these observations with our own, it seems that the most optimal selective 
molecule would bind the phosphotyrosine binding pocket as well as both the R362 and K364 
residues in order to generate the most selectivity.  
6.3) Proposed Experiments 
The future of targeting SHP2 hinges on several unknowns. Drug design is a potentially 
significant hurdle. If a selective molecule cannot be developed, then the risk for unexpected 
adverse events becomes worrisome. This is especially true with respect to SHP2 versus SHP1 
selectivity, since there is the potential for developing hematopoietic malignancy if SHP1 is 
inhibited (215-218). The data provided in the selectivity study may be useful in the design of 
an ideal inhibitor, one that can achieve many-fold selectivity over today’s best small molecules. 
Rational design is an important factor to consider here, since drug screens conducted to find 
SHP2 inhibitors cannot be negatively selected at the same time for SHP1. This has resulted in 
troublesome compounds being discovered as leads. I envision that the data provided through 
molecular modeling can help the drug designers in the SHP2 field to pursue design of a 
peptidomimetic that is both drug-like and selective. 
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 Drug design issues are dwarfed by a larger unanswered question in the field: Will 
inhibition of SHP2 impact breast tumors? As of today, this question has not been tested 
directly. The most immediate experiment that needs to be performed is pharmacologic 
inhibition in mouse models of breast cancer. II-B08 has proof of principle established in lung 
cancer xenografts, suggesting this molecule is indeed bioavailable. There are many appropriate 
breast cancer models that can be tested in this line, including transgenic, spontaneous HER2-
positive tumors (driven by MMTV-Neu) and xenograft transplants of cell lines. The efficacy 
against metastasis by SHP2 inhibitors has yet to be evaluated in mice, as well. This should be a 
relatively trivial experiment, however, since tumors grown in mice are often dissected for 
analysis by pathological or immunohistochemical staining. Primary target sites of metastasis 
(e.g., lung and liver) can be excised at the same time. More to point, the tail-vein injection can 
be used as a direct metastasis experiment, bypassing the need to first establish a primary 
tumor.  
 Will inhibition of SHP2 impact cancer metastasis? Previous studies have suggested a 
correlation between metastasis to lymph nodes and overexpression of SHP2 (28). In addition, 
our studies into the role of SHP2 in cell motility imply that pharmacologic inhibition should 
suppress metastasis. This motility experiment can be expanded, however, to accommodate 
other stimuli of protrusions. EGF signaling is known to be important for a large subset of 
breast cancer, but is the defect of lamellipodial persistence we observed carried through into 
stimulation by other growth factors? This facet of SHP2 signaling should be explored further, 
since our study was the first to demonstrate a role for SHP2 in regulating dynamics of 
lamellipodia; however, the lack of response to EGF following SHP2 inhibition fails to account 
for all of the wound healing defects we observed. Regulation of FAK by SHP2 is clearly not the 
132 
only player in this process, either, since our rescue experiment using the FAK inhibitor was 
unable to correct the less motile phenotype observed under normal serum conditions. Further 
exploration into this matter would be particularly valuable. Other experiments controlling pro-
metastatic phenotypes controlled by SHP2 (e.g., proteolysis, 3D cell morphology) have yet to 
be performed in depth. If SHP2 is indeed important for metastasis, it will be critical to 
determine the mechanisms that promote these phenotypes. 
6.4) Conclusions 
In total, the studies presented in this thesis add incremental evidence to three facets of SHP2 in 
breast cancer: 
1) EGFR-HER2 crosstalk is a complicating factor in therapy, and alternative strategies 
may be valuable for treating HER2-positive breast cancer. 
2) SHP2 can promote motility of breast cancer cells by controlling FAK, providing one 
more line of evidence supporting the use of an anti-SHP2 approach in therapy. 
3) Better selectivity can be achieved in future anti-SHP2 inhibitors, and the 
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